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PART I 
PARTIAL AMINO ACID SEQUENCE OF RAT SKIN TRYPTASE 
CHAPTER I 
INTRODUCTION 
Tryptase has been isolated and partially characterized 
from a variety of species including rat, dog, bovine, and 
human. The potential roles of tryptase in pathogenesis of 
different diseases have attracted close attention of many 
investigators in recent years. 
Tryptase is a serine protease which hydrolyses peptide 
bonds on the C-terminal side of either arginine or lysine. 
However, tryptase does not exhibit general proteinase activity 
and has a stronger subsite preference and a higher degree of 
selectivity toward model substrates than trypsin. 
Recently, amino acid sequences of tryptase from mouse, 
dog, and human have been deduced from the nucleotide sequence 
of cDNA cloned from mast cell cDNA libraries. The sequences 
show some basic structural differences between tryptase and 
trypsin. In this lab, a tryptase has been purified from rat 
skin and intensively characterized. The rat skin tryptase 
shows similar inhibitor and substrate specificity to other 
tryptases. However, rat skin tryptase also appears to have 
its unique chemical properties. 
In this study, partial amino acid sequences of rat skin 
2 
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tryptase have been determined using the Edman procedure and 
compared with other tryptase sequences. The results have 
revealed some profound structural differences and some common 
features among tryptases. These interesting observations 
suggest that specific amino acid residues responsible for the 
functional specificity of tryptases can be identified. The 
information obtained from this study can be very helpful in 
designing fulture experiments to explore the structure and 
function relation of tryptases. 
CHAPTER II 
LITERATURE REVIEW 
1. Biological Function 
4 
Tryptase is a trypsin-like serine proteinase found in 
secretory granules of mast cells (Schwartz et §.!.. 1981) . 
Although the precise function of tryptase in vivo is not 
clear, many possible biological and pathological roles have 
been postulated based on a large number of in vitro studies. 
There is evidance that tryptase may have anticoagulant 
effects. Tryptase can hydrolyze fibrinogen and inactivate the 
thrombin-induced clotting of fibrinogen (Schwartz et al. 
1985) . Tryptase also degrades high molecular weight kininogen 
(HMWK) (Maier et al. 1983). HMWK is known to convert 
prekallikrein to kallikrein which then can initiate the 
intrinsic coagulation pathway by activating factor XIIa. By 
hydrolyzing HMWK, tryptase rapidly inactivates HMWK-dependent 
coagulation activity. The role of tryptase in the conversion 
of low molecular weight kininogen to bradykinin, a potent 
vasodilator, is controversial (Schwartz et al. 1986, Proud et 
al. 1988). Although a systematic defect of coagulation does 
not usually occur, the anticoagulant effect may be important 
in some local tissue environments such as in mucosa, skin, and 
lung (Schwartz 1990) . However, tryptase was shown to convert 
prothrombin to thrombin (Kido et al. 1985). The potential 
5 
biological role of this activity remains to be explained. 
Tryptase has been suspected to be a mediator of airway 
smooth muscle hyperresponsiviness that is characteristic of 
asthmatic individuals {Caughey 1989, Sekizawa et al. 1989). 
The evidence showed that dog bronchial smooth muscle 
contraction was prevented by a tryptase inhibitor. Vasoactive 
intestinal peptide {VIP) is a potent relaxant of various types 
of smooth muscles {Matsuzaki _g.t_ al. 1980, Said 1987). Peptide 
histidine-methionine {PHM) is also a potent bronchodilating 
peptide that co-exists with VIP and regulates blood flow and 
bronchial smooth muscle tone {Itoh et al. 1983, Lundberg et 
gl. 1984, Palmer et al. 1986, Linder et al. 1987). Substance 
P {SP) , on the other hand, is believed to be a potent 
bronchoconstrictor {Lundberg et al. 1983) which can cause mast 
cell degranulation in lung {Barrett et al. 1986) and regulate 
the vasodilator activity of calcitonin gene-related peptide 
{CGRP), a potent vasodilator in skin {Brain 1988) and lung 
{Palmer~ al. 1987). Tryptase selectively hydrolyzed the 
bronchodilation peptides VIP, PHM, and CGRP but not the 
bronchoconstriciton peptide SP {Caughey et al. 1988, Tam & 
Caughey 1990, Walls et al. 1992). The evidence suggests that 
tryptase may contribute to smooth muscle contraction by 
regulating the activity of the neuropeptides. 
A potential role for tryptase in peptide prohormone 
processing has been proposed {Cromlish et al. 1987, Proctor et 
al. 1991). Adrenocorticotropic hormone {ACTH) is a pituitary 
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hormone which regulates the growth and function of the adrenal 
cortex. Human pituitary tryptase selectively cleaves the 
ATCH(l-39) to form ACTH(l-15) and ACTH(16-39). Atrial 
natriuretic factor (ANF) is a peptide hormone produced by the 
heart (Debold 1985) which promotes a reduction of blood volume 
and pressure and causes a generalized vasodilation. The pro-
ANF, which consists of 126 amino acids, can be converted to 
active ANF by human and bovine tryptase. 
Processing of certain enzymes and proteins suggests other 
potential roles of tryptase. Tryptase was shown to cleave 
complement protein C3 to generate C3a, a chemotactic factor, 
in vitro (Schwartz et al. 1983). 
A role for tryptase in the degradation of human 
extracellular matrix has been proposed. Rapid activation of 
purified prostromelysin or pro-matrix metalloprotease 3 (MMP-
3) can result from incubation with physiological 
concentrations of tryptase (Gruber et al. 1988, 1989). The 
active stromelysin in turn converts the procollagenase to 
active collagenase (Vater et al. 1983, Ito et al. 1988). 
Active stromelysin is also capable of degrading other 
extracellular matrix components such as type IV and IX 
collagen, f ibronectin, laminin, gelatin, and proteoglycans 
(Chin et al. 1985, Okada, §.t. al. 1986, Okada et al. 1989). 
The evidence indicates that tryptase may play an important 
role in connective tissue turnover such as in the case of 
rheumatoid arthritis and various fibrotic conditions. 
7 
Tryptase was found to hydrolyze the DNA binding protein 
histone Hl effectively. The observation suggested a possible 
role for tryptase in the organization of DNA during cell 
turnover {Harvima et g,,l. 1989}. In a recent study {Ruess gt. 
g,l. 1991}, tryptase was implicated as a potent mitogen which 
strongly stimulates DNA synthesis and cell growth in cultured 
rat fibroblast and chinese hamster lung cell lines. 
Tryptase is stored in an active form in mast cells and is 
released upon mast cell degranulation {Schwartz 1990b, 
vassimon & Rothschild 1990}. As a unique marker for the human 
mast cell {Craig & Schwartz 1989}, tryptase has been used as 
a useful clinical indicator of mast cell activation {Matsson 
et al. 1991} . The specific cellular localization, the 
abundance in human tissues, and the stability in serum make 
tryptase a preferred mast cell activation indicator over 
histamine which has been used traditionally in determination 
of anaphylaxis. Histamine can be secreted from not only mast 
cells, but also from basophil. The histamine level in serum 
declines to baseline within 15-60 minutes while tryptase has 
a half life in the circulation of about 2 hours {Schwartz et 
al. 1989}. 
2. Chemical And Physical Properties 
Information regarding tryptase has accumulated rapidly in 
the past few years. Shortly after the partial purification of 
a neutral proteinase with characteristics of a tryptase from 
8 
human uterine cervix (Ito tt al. 1980), a tryptase was 
purified and characterized from human pulmonary mast cells 
(Schwartz ~ .sY.,. 1981) . Since then, human tryptase has been 
purified from lung (Smith .e.t. al. 1984), pituitary (Cromlish .e.t. 
gl. 1987), skin (Harvima ~al. 1988), as well as from a human 
mast cell line established from peripheral blood of a patient 
with leukemia (Butterfield~ al. 1990). Non-human tryptases 
have been purified from rat peritoneal cavity mast cells (Kido 
g.t. gl. 1985, Lagunoff .e.t. gl. 1991) , rat skin (Braganza & 
Simmons 1991) , dog mastocytoma cells originally isolated from 
skin tumors (Caughey et al. 1987), and mast cells from bovine 
liver capsula (Fiorucci et al. 1992). 
A total of seven cDNAs and two genes for tryptases have 
been cloned and sequenced. The first cDNA for tryptase was 
obtained from a dog mastocytoma cDNA library (Vanderslice et 
al. 1989). Two cDNAs for human lung tryptases were cloned and 
sequenced from the same human lung mast cell cDNA library 
(Miller~ al. 1989, 1990). The two lung tryptases exhibited 
90%' amino acid identity and were named O!-tryptase and {J-
tryptase. After screening a human skin cDNA library, three 
skin cDNAs for tryptases with over 90%' identities among them 
were sequenced and called human skin tryptase-1, -2, and -3 
(Vanderslice ~ al. 1990). Human skin tryptase-2 is identical 
to human lung {J-tryptase. The gene for human skin tryptase-1 
was cloned and sequenced using the human skin tryptase-2 cDNA 
to screen the genomic library. In mouse, where no tryptase 
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has been purified, two cDNAs and a gene for tryptase were 
identified from mouse mast cell lines. Mouse mast cell 
protease-6 {Reynolds ~ s.J... 1991) is identical to mouse mast 
cell tryptase-1 which has 71% of amino acid identity to mouse 
mast cell tryptase-2 {Chu 1990). The cDNA sequences provide 
us with a source for the basic amino acid sequence information 
about tryptases. 
Tryptase is a trypsin-like serine protease that 
hydrolyzes peptide bonds on the carboxyl side of an arginine 
or lysine residue. However, tryptase has a more restricted 
substrate specificity than trypsin. Amino acid residues 
around the arginine or lysine residues of the substrate 
greatly affect the rate of substrate hydrolysis by tryptase 
{Schwartz et al. 1981, Tanaka et al. 1983, Kido et al. 1985, 
Smith et al. 1984, Cromlish et al. 1987, Braganza & Simmons 
19 91) . Tryptase is inhibited by the serine protease inhibitor 
di-isopropylfluorophosphate {DFP), trypsin inhibitors such as 
N-tosyl-L-lysine chloromethylketone {TLCK), and the natural 
microbial-derived inhibitors leupeptin and antipain. Other 
trypsin inhibitors such as lima bean trypsin inhibitor {LBTI) , 
soybean trypsin inhibitor {SBTI) , and ovomucoid have little or 
no effect on tryptases. Chymostatin, N-tosyl-L-phenylalanine 
chloromethylketone (TPCK) , pepstatin, and ethylenediamine-
tetraacetic acid {EDTA) do not inhibit the enzyme. 
Al though there are many common properties among tryptases 
from different sources, they exhibit different responses to 
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certain inhibitors. Rat skin tryptase, for example, is 
inhibited by aprotinin {Trasylol) {Braganza & Simmons 1991) 
while human lung tryptase is not {Smith et al. 1984). The 
thiol-group inhibitor, p-chloromercuribenzoate {PCMB), 
inhibits human pituitary tryptase but not human lung, human 
uterine cervix, rat, or dog tryptase. While human skin 
tryptase and human 1 ung tryptase are inhibited by benzamidine, 
human peripheral blood mast cell tryptase is insensitive to 
the inhibitor. Rat peritoneal mast cell tryptase is sensitive 
to ~-1-antitrypsin which, on the other hand, has little 
inhibitory effect on rat skin tryptase and other purified 
tryptases. Rat peritoneal mast cell tryptase was reported to 
be associated with a unique endogenous Kunitz-type trypsin 
inhibitor {or basic pancreatic trypsin inhibitor), called 
trypstatin {Kido et al. 1985, 1988) . No associated trypstatin 
has been detected in other tryptases including rat skin 
tryptase. 
The reported molecular weight of native tryptases varies 
from 110,000 to 150,000 depending on the source of the enzyme. 
Tryptase is a tetra.mer with subunits in the molecular weight 
range of 30, 000 to 38, 000. Variation of the reported 
molecular weights may be due to the extent of glycosylation of 
the tryptase. Tryptase treated with N-Glycanase {a 
deglycosylation enzyme) had a subunit molecular weight of 
32,400 for human pituitary tryptase and about 27,000 for rat 
skin tryptase. Putative glycosylation sites detected from the 
11 
cDNA-deduced amino acid sequences suggest that different 
tryptases may have different numbers of glycosylation sites. 
Functionally, tryptase share a great deal of their conunon 
physical and chemical properties and at the same time exhibit 
a substantial degree of variations among them. Structurally, 
despite of the high homology among tryptases, they also reveal 
a great extent of diversity in the amino acid sequences. The 
functional and structural properties of a group of similar 
enzymes will provide the fundamental information necessary for 
correlating enzyme functions to their structures. For 
example, chymotrypsin, trypsin and elastase are members of the 
serine protease family. Their functional properties have been 
well related to their structural features. Serine 189 in the 
substrate binding pocket contributes to the specificity of 
chymotrypsin which requires an aromatic or bulky side chain 
such as tyrosine, phenylalanine, tryptophan and methionine in 
the P1 site of the substrate. The same position occupied by 
aspartate instead results in a totally different substrate 
specificity in trypsin. The acidic aspartate residue in 
trypsin limits its binding only to substrates with basic 
residues such as lysine and arginine. In elastase, the 
binding pocket is blocked because of the replacement of two 
glycine residues in the substrate binding site by two bulkier 
valine and threonine residues. The structural feature is 
reflected by the functional specificity of elastase to smaller 
residues such as alanine, glycine, and serine. 
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In order to draw a correct correlation, the structure, or 
amino acid sequence, must be the sequence of the functional 
enzyme characterized. The data gathered up to date are not 
sufficient for the correlation. Human skin tryptase-1 cDNA 
was matched to tryptase purified from human lung based on the 
24 amino acids at the N-terminal of the characterized enzyme. 
However, human skin tryptase-2 cDNA also has 24 identical 
amino acids at the N- terminal. Thus, the amino acid sequences 
derived from the cDNAs have not been precisely assigned to any 
specific human tryptase purified and characterized. 
Sequencing through the Edman procedure can provide direct 
correlation of the function of a specific tryptase with its 
structural properties. Undoubtedly, further exploration of 
the structural and functional properties of tryptase will lead 
to a deeper understanding of the role of tryptase in nature 
and have a great pharmacological significance in the near 
future. 
3. Purpose Of The Project 
The main purpose of this project is to investigate the 
potential structure and function relationship among tryptases. 
The biological significance of tryptase can be appreciated as 
a specific component of mast cell granules. Tryptase purified 
from different sources have demonstrated their common and 
unique chemical and amino acid sequence properties as seen in 
the review section above. The observations raise our interest 
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in preparing to investigate the relation between tryptase 
functions and their structural features. In order to draw a 
correct correlation, it is very important to know that the 
primary structure obtained belongs to the enzyme 
characterized. To achieve this goal, I tried to obtain as 
much sequence as possible from rat skin tryptase using the 
Edman procedure. The sequence obtained here provides some 
important preliminary information about the structural 
features of rat skin tryptase and serves as a good starting 
point for continuing the project in the future. 
Specifically, a large amount of tryptase was purified 
from rat skin. The purity of tryptase was verified by SDS-
PAGE and reversed-phase HPLC. The unstable cystine residues 
in tryptase were converted to stable S-carboxymethylcysteine 
through an alkylation procedure before the Edman reaction. 
The alkylated proteins were enzymatically or chemically 
fragmented. The resulting peptides were subjected to 
different types of HPLC chromatography including the use of 
gel permeation and reversed-phase columns. The purified 
peptides were sequenced by the Edman procedure using an 
automated sequencer. Rat skin tryptase peptides were compared 
with other tryptase sequences. The study exhibited some very 
interesting observations. 
A. Materials 
CHAPTER III 
MATERIALS AND METHODS 
Rat skin (Sprague-Dawley), was obtained from other labs 
or Pel-Freez Biologicals, Rogers, Arkansa. NaHP04 , Na~P04 , 
NaCl, ethanol, glycerol, acetic acid, and glutaraldehyde were 
from Mallinckrodt, St. Louis, MO. Ethylenediaminetetraacetic 
acid (EDTA), agarose-glycyl-glycyl-p-aminobenzamidine gel 
(PAB), benzamidine.HCl, concanavalin A-agarose gel (Con A), ~-
methyl-D-mannoside, NaN3 , benzoyl-L-arginine ethyl ester 
{BAEE), iodoacetic acid, acetonitrile, trifluoroacetic acid, 
bovine serum albumin fraction V (BSA), and Mark VI protein 
molecular weight standards were from Sigma Chem. Co., St. 
Louis, MO. Bradford Reagent for protein assay was from Bio-
Rad Laboratories, Richmond, CA. Amrnomium sulfate was obtained 
from Schwarz Mann Biotech. Div. of ICN Biomedicals, Inc. , 
Camgridge, MA. (3H)iodoacetic acid was from Amersham, 
Arlington Heights, IL. Dialysis tubing was from Bethesda 
Research Labs, Gaithershurg, MD. Centricon-30 
microconcentrator units were from Amicon Division, W.R. Grace 
& Co., Danvers, MA. Homogeneous gels (12%) and SOS buffer 
strips were from Pharmacia,. N-Glycanase cloned from 
14 
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£lavobacterium meningosepticum and expressed in .IL.. Coli. was 
obtained from Genzyme. Trypsin was from Serva, NJ. 
Lysylendopeptidase C was from Wako Fine Chem., Japan. 
B. Methods 
1. Purification Of Rat Skin Tryptase 
Sprague-Dawley rats were decapitated and the skins 
removed and stored at -20 °C until use. Alternatively, rat 
skin was obtained from Pel - Freez Biological, Rogers, Arkansas. 
The fur was clipped away as close as possible to the epidermis 
using an Ostar Professional Animal Grooming Clipper, Model A-
S, with a No. 80, Size 40 blade. The fat layer and the thin 
cutaneous muscle {Hebel & Stromberg 1976) were scraped off 
using a stainless steel blade. The skins were then rinsed 
well in tap water followed by distilled water and minced in a 
Universal No. 3 meat grinder through two cycles. For each 
purification, about 400 g of skin were used. All subsequent 
steps were carried out at 4 °C unless otherwise indicated. 
The minced skin was weighed and homogenized at a 1: 9 
{w/v) ratio of the homogenization buff er {Appendix A) using a 
Waring blender, model PB-5, at full speed for 6-8 times with 
20 second rest intervals. The homogenate was filtered through 
a nylon mesh in a Buchner funnel under vacuum. The volume of 
the filtrate was recorded and 1 ml was saved for analysis. 
The filtrate was brought to 25% {NH4 ) 2804 saturation by 
adding 139 g of the sal t/l. The solution was allowed to 
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equilibrate for 4-6 hours. After centrifugation at 13,700 xg 
for 15 minutes in a Sorvall GSA rotor at 4 °C, the supernatant 
was brought to 80% {NH4 ) 2804 by adding 361. 5 g of the salt/l 
quickly {Taylor 1953). The solution was allowed to sit 
overnight. The solution was then centrifuged at 13, 700 xg for 
15 minutes. The pellet was resuspended in 100 ml of the 
dialysis buff er {Appendix A) and dialyzed against two changes 
of 6 1 of the dialysis buffer overnight. 
The dialyzed fraction was centrifuged at 23,700 xg in a 
Sorvall SS-34 rotor for 15 minutes and applied to an agarose-
glycyl-glycyl-p-aminobenzamidine {PAB) affinity column {1.5 x 
20 cm) equilibrated with the dialysis buffer at a flow rate of 
25 ml/h at room temperature. The sample itself was kept on 
ice during application to the column. The column was then 
washed with 50 ml of the PAB equilibration buffer {Appendix A) 
at room temperature and then moved to 4 °C for 1 hour before 
washing again with another 25 ml of the same buffer. A 
concanavalin A-agarose {Con-A) column (1 x 10 cm) , previously 
washed with 20 ml of the Con-A activation buffer {see Appendix 
A) followed by PAB equilibration buffer, was connected to the 
PAB column. The enzyme was eluted from the PAB column to the 
Con-A column by applying 40 ml of the PAB elution buffer 
{Appendix A) at a flow rate of 10 ml/h. After the 
application, the Con-A column was disconnected from the PAB 
column and washed with 10 ml of the PAB equilibration buffer. 
The enzyme was washed off the Con-A column with the Con-A 
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elution buffer (Appendix A) at a rate of 5 ml/h. The 
fractions were collected in 1 ml/tube and assayed for enzyme 
activity. Those fractions containing activity were pooled and 
concentrated using several Centricon-30 microconcentrator 
units (Am.icon). After concentrating each sample to 50-100 µl, 
2 ml of the dialysis buffer was added to each unit and 
concentrated until 50-100 µl was left in each unit. This step 
was repeated once. Each unit was then rinsed twice with 100 
µl of the dialysis buffer. The final fractions were pooled 
together and stored at 4 °C. The PAB column was washed with 
PAB wash buffer (Appendix A) followed by PAB equilibration 
buffer at room temperature and stored at 4 °C. The Con-A 
column was washed with the Con-A wash buffer (Appendix A) and 
stored in Con-A activation buffer at 4 °C. 
Enzyme activity was measured by monitoring the hydrolysis 
of benzoyl-L-arginine ethyl ester (BAEE) at 253 nm (Schwert & 
Takenaka 1955). The sample cuvette contained 440 µl of the 
assay buffer (Appendix A), 10 µl of the sample, and 50 µl 10 
mM BAEE. The reference cuvette contained 450 µl of the assay 
buffer and 50 µl of the 10 mM BAEE. The initial rate (0-5 
minutes) was measured in a Gilford Response Spectrophotometer. 
One unit of activity was defined as 1 µmole of substrate 
hydrolysed per minute. Specific activity is defined as unit 
activity per mg of protein and calculated according to the 
following formula: 
Specific Activity= (~3,min) (0.5 ml)/(0.9 x mg protein/ml x 
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ml} 
where A.Az,s31min is the rate of BAEE hydrolysis, O. 9 is the 
absorbance change for total cleavage of BAEE in the cuvette, 
mg protein/ml is the protein concentration of the sample, and 
ml is the volume of the sample used in the assay. 
Protein concentration was determined using the microassay 
procedure from Bio-Rad (Bradford 1976} . Bovine serum albumin 
fraction V from Sigma was used as a standard. The standard 
curve and the sample protein concentration were obtained at 
As9s on the Gilford Response Spectrophotometer. 
The purity of the protein was checked by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SOS PAGE} and 
reverse phase high performance liquid chromatography (HPLC}. 
2. SOS-PAGE 
SOS-PAGE was performed under reducing conditions on a 
PhastSystem from Pharmacia according to the manufacturer's 
manual. Protein samples were concentrated in a Centricon-30 
unit to 50 µg/ml or higher. The recovery of tryptase from the 
Centricon-30 was above 90% in water. The samples were mixed 
with the sample buffer (Appendix B} at a 1:1 ratio and boiled 
for 5 minutes before application of the samples to the gels. 
PhastGel homogeneous 12. 5 or PhastGel gradient 10-15 gels were 
used for the separation. The samples were applied to the gel 
using size 6/4 sample applicators and separated with the sos 
buff er strips using the following program: 
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SEP. PROGRAM 1 
sample Application Down At 1.2 0 vh 
sample Application Up At 1.3 0 vh 
Sep. 1.1 250 v 10 mA 3 w 15 oc 1 vh 
Sep. 1.2 250 v 1 mA 3 w 15 oc 1 vh 
Sep. 1.3 250 v 10 mA 3 w 15 oc 80 vh 
The gel was stained with silver in the development unit using 
the following program: 
DEV. PROGRAM 1 
I n - Ou t - Time Temp . 
Steps Solutions Port Port min oc 
1 50% Eth, 10% HAc 2 0 2 so 
2 10% Eth, 5% HAc 3 0 2 50 
3 10% Eth, 5% HAc 3 0 4 50 
4 Glutaraldehyde 4 0 6 50 
5 10% Eth, 5% HAc 3 0 3 50 
6 10% Eth, 5% HAc 3 0 5 50 
7 MQ Water 5 0 2 50 
8 MQ Water 5 0 2 50 
9 Silver Nitrate 6 0 13 40 
10 MQ Water 5 0 0.5 30 
11 MQ Water 5 0 0.5 30 
12 Developer 7 0 0.5 30 
13 Developer 7 0 4 30 
14 
15 
5% HAc 
6% Glycerol 
8 
9 
0 
0 
2 
3 
50 
50 
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Eth stands for ethanol, MQ water for milli Q water, and HAc 
for glacial acetic acid. The solutions used are given in 
Appendix B. Protein standards from Sigma included bovine 
albumin with a molecular weight of 66,000, ovalbumin (43,000}, 
pepsin (34,700}, trypsinogen (24,000}, P-lactoglobulin 
(18,400}, and lysozyme (14,300}. The relative mobility (Rf} 
of a protein was determined according to the formula: Rf = 
Distance of protein migration/Distance of tracking dye 
migration. The Rf values (abscissa} were plotted against the 
known molecular weights (ordinate} on a semi-logarithmic 
paper. The molecular weight of a sample was either 
extrapolated from the determined sample Rf value in a standard 
curve or calculated from the regression equation derived from 
the logarithmic values of the molecular weight and the Rf 
values of the protein standards. A standard was prepared for 
each gel. 
3. Reversed-Phase HPLC 
A Varian model 5500 HPLC system was used. The protein 
and peptides were separated based on their hydrophobicities 
using butyl- (C4}, octyl- (CS}, and octadecyl- (C18} columns 
from Rainin Instrument Co., Inc., Woburn, MA. The samples 
were dissolved in 6 M quanidine-hydrochloride solution. The 
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mobile phase was delivered as a linear gradient of increasing 
acetonitrile in O.lt trifluoroacetic acid (TFA) at O.S ml/min. 
solution A contains 0.1% of TFA in water. Solution B contains 
o.1t of TFA in acetonitrile. A typical separation program is 
shown as the following: 
Time Solvent A Solvent B Flow Rate 
(min) (%) (%) (ml/min) 
0 100 0 o.s 
60 40 60 o.s 
62 0 100 o.s 
64 100 0 o.s 
Protein peaks were detected at 206 nm using a UV mornitor and 
collected into plastic tubes. The collected fractions were 
dried by speed vacuum centrifugation. 
4. Enzymatic Deglycosylation Of Tryptase 
Purified tryptase was concentrated to 2 mg/ml in MQ water 
using a Centricon-30 unit. Tryptase (3.2 µg) was denatured by 
boiling for s minutes in 20 µl of 100 mM Tris-HCl, pH 8, 
containing so mM P-mercaptoethanol and O. st SDS. To the 
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denatured sample was added 5 µl of 7.5% Nonidet P-40 followed 
by 5 µl {1.25 units) of recombinant peptide-N-Glycosidase F 
{N-Glycanase) in a buffer containing 50% glycerol, O .15 M 
NaCl, 1 mM EDTA and 80 mM sodium phosphate. The reaction was 
incubated at 37 °c. After 20 hours, an additional 1.5 µl {0.4 
units) of N-Glycanase was added and the reaction was allowed 
to continue overnight. The reaction was terminated by boiling 
for 5 minutes. In a parallel control experiment, the N-
Glycanase was replaced by the same volume of the enzyme 
buffer. In another control experiment, the reaction contained 
all of the components except tryptase which allowed detection 
of any N-Glycanase on a gel if it occured. The samples were 
subjected to SDS-PAGE along with Sigma VI molecular weight 
standards. Gels were developed with silver stain using the 
Pharmacia PhastSystem as described above. 
5. Alkylation of Tryptase 
Since cysteine residues are subject to autoxidation, they 
must be converted to more stable derivatives before 
sequencing. Iodoacetic acid was used to radiolabel and 
convert the cysteine residues to a stable s-
carboxymethylcysteine {Allen 1986) . 
The purified tryptase {about 200 µg) was dissolved in a 
solution containing 6 M quanidine hydrochloride by adding 0.7 
g of the salt and 400 µl of a Tris-HCl buffer {Appendix C) and 
then vortexing well. The protein was reduced by dissolving 
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o.2 mg of DTT in the solution followed by incubation at room 
temperature for 1 hour. A 50 µl solution of [3H]-iodo-acetic 
acid (Appendix C} was added. The solution was capped and 
sealed in the dark at room temperature for 30 minutes. The 
reaction was driven to completion by addition of 4. 8 mg of DTT 
to the solution followed by incubation in the dark at room 
temperature for 1 hour. Non-radioactive iodoacetic acid 
solution (Appendix C} was then added to the mixture and 
incubated for another 30 minutes in the dark. Finally, the 
reaction was terminated by addition of 60 µl of 6 N HCl 
solution (Appendix C}. 
The unincorperated iodoacetic acid and other salts were 
removed from the alkylated enzyme using a 1 x 30 cm Sephadex 
G-25-80 column. The column was equilibrated in either an 
ammonium bicarbonate buffer (Appendix C} or a formic acid 
solution (Appendix C} depending on the digestion method to be 
used. The column was calibrated using 1 or 5 mg of bovine 
serum albumin at a flow rate of 30 ml/h. The fractions were 
collected in about 1 ml/tube. Fractions containing the 
protein were detected at 280 nm. After the calibration, the 
alkylation mixture was applied onto the column. The fractions 
collected were counted for radioactivity to confirm the 
presence of the sample and then dried by speed vacuum 
centrifugation before chemical or enzymatic fragmentation. 
6. Enzymatic Cleavage Of Tryptase 
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Trypsin was used to catalyze the hydrolysis of lysyl and 
arginyl peptide bonds in the alkylated tryptase. Tryptic 
digestion was conducted at a protein:trypsin molar ratio of 
100: 1 in a buffer containing O .1 M NH.HC03 and O .1 mM CaC12 , pH 
e. About 40 µg of the alkylated tryptase was mixed with 0.4 
µl of the 1 mg/ml trypsin in 0.1 mM HCl, 10 µl of 1 mM CaC12 , 
and 90 µl of 0.1 M NH4HC03 , pH 8. The reaction was allowed to 
continue at 37 °C for 16 hours and stopped by speed vacuum 
centrifugation. 
Lysylendopeptidase-C (Lys-C) was used to catalyze the 
hydrolysis of lysyl peptide bonds in tryptase. The reaction 
mixture contained 100 µl of 50 mM Tris-HCl, pH 9, 1 µg of Lys-
C and 100 µg of the alkylated tryptase. The reaction was 
allowed to continue at 37 °C for 6 hours and stopped by speed 
vacuum centrifugation. 
7. Separation And Purification Of Peptides 
Digestion of tryptase was first evaluated by running a 
small amount of the sample on 12% SDS-PAGE. Then the peptides 
were separated and purified by HPLC. 
Separation of the tryptic peptides was carried out using 
a C18 column. The sample was dissolved in 6 M quanidine-HCl 
solution and injected into the HPLC. The mobile phase 
contained a linear gradient of increasing acetonitrile from 0% 
to 60% in 60 minutes. The peaks from the separation were 
collected in separate tubes, labeled and centrifuged under 
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vacuum. Some peaks which had overlap shoulders were separated 
again using a CS column. The acetonitrile concentration was 
increased from 10% to 20% over 20 minutes. 
Peptides from the Lys-C digest were separated using a gel 
permeation column {Bio-Sil TSK-125 from Bio-Rad). Samples 
were dissolved in 6 M quanidine-HCl. The mobile phase 
contained 6 M quanidine-HCl and 10 mM potassium phosphate, pH 
6. Peptide peaks were collected in separate plastic tubes. 
Peptides separated by the gel permeation column were subject 
to a second purification using a C4 hydrophobic column. The 
acetonitrile gradient was increased from 0% to 60% in 30 
minutes. The fractions were dried by speed vacuum 
centrifugation. 
8. Amino Acid Sequence Determination 
Reverse-phase HPLC purified peptides were sequenced by 
the Edman procedure using an ABI 477A automated sequencer 
equipped with on-line PTH analyzer 120A. 
CHAPTER IV 
RESULTS 
1. Purification Of. Rat Skin Tryptase 
A large amount of tryptase had to be purified from rat 
skin in order to satisfy the requirements of the project. A 
total of 2~000 µg of tryptase was isolated from 22 
purifications. 
Table 1. 
A typical purification result is shown in 
In the purification procedure, a high salt concentration 
(O.S M NaCl} was used to facilitate extraction of tryptase 
from rat skin. Precipitation of protein in the crude extract 
at 25- 80% ammonium sulfate saturation removed large amounts of 
contaminating proteins. As observed in most of the 
purifications, the enzyme activity measured at this step was 
lower than expected. It may be due to either the elimination 
of other non-tryptase BABE activity in this step or 
interference of residual ammonium sulfate after an overnight 
dialysis. The salt did not significantly interfere with the 
binding of tryptase to the PAB column at room temperature. 
In one purification, the fat and the cutaneous muscle 
layers associated with the skin were not removed prior to 
homogenization to see if this affected the ability to obtain 
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Fractions Volume Prat.Cone. Tot.Prat. Act. 
(ml) (mg/ml) (mg) (U/ml) 
Crude 
Extract 1530 2.23 3412 0.085 
(NH4) 2S04 
25-80%' 95 9.81 932 0.216 
PAB/Con A 
Columns 2.7 0.032 0.085 4.943 
Table 1. Purification Of Rat Skin Tryptase. 
Sp.Act. Tel.Act. 
(U/mg) 
(U) 
0.038 130.1 
0.022 20.5 
154 13.2 
Yield 
(Ut) 
100 
16 
10 
Pur.Fact. 
(Fold) 
1 
0.6 
4053 
l:V 
...J 
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purifed enzyme. The presence of components from the fat and 
muscle layers seriously decreased the flow rate of the PAB 
affinity column step. In the subsequent purifications, these 
layers were removed as in the original published procedure. 
The PAB/Con-A step gave a purification factor of about 4,000-
fold and yielded a recovery of BAEE hydrolyzing activity of 
about 10%. The result is consistant with the previous report 
in which the calculated recovery based on cleavage of the 
specific substrate D-Ile-Pro-Arg-pNA was 35%, giving an enzyme 
preparation purified 14,000 fold {Braganza & Simmons 1992). 
A typical preparation from about 300-400 g skin tissue yielded 
about 80-90 µg of purified tryptase. The procedure was used 
successfully a few times to obtain about 150 µg of highly 
purified tryptase in one purification from a larger amount of 
skin. In one isolation, over 230 µg of tryptase was purified 
using the procedure. However, scaling up this procedure for 
the preparation of larger amounts of tryptase was difficult. 
The purity of tryptase was checked with SDS-PAGE and 
reversed-phase HPLC before it was used for sequencing or 
antibody production. Figure 1 shows a broad band of the 
purified tryptase on a SDS-PAGE gel. The molecular weight was 
determined to be 31, 000 ± 1, 000 {Figure 2). The broad band is 
due to different extents of glycosylation of the enzyme {see 
below). Reversed-phase HPLC of the enzyme {Figure 3) on a C4 
hydrophobic column showed a single 
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Figure 1. SOS-PAGE Of Purified Tryptase. Sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SOS-PAGE) was 
performed using a Pharmacia PhastSystem. Purified rat skin 
tryptase (0.7 µg) was separated on a 12.5% homogeneous gel 
under denaturing and reducing conditions. The positions of the 
molecular weight standards are indicated next to the sample. 
The gel was developed with silver stain. 
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Figure 2. Molecular Weight Of Tryptase By SDS-PAGE. 
Purified rat skin tryptase was separated on a 12.5% 
homogeneous gel using a Pharmacia PhastSystem. Six molecular 
weight standards on the indicated molecular weight are shown 
in the open circles. The molecular weight of the standards at 
a common logarithm scale are plotted against the corresponding 
Rf values as defined in the text. An average Rf value for the 
broad tryptase band is shown in the solid circle. 
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Ovalbumin 45,000 
a Pepsin 34,700 
Tryptase 
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,8-Lactoglobulin 18,400 
Lysozyme 14,300 
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Figure 3. Reversed-Phase HPLC Of Purified Tryptase. 
Purified rat skin tryptase was subjected to reversed-phase 
HPLC chromatography using a C4 column. The separation 
conditions are shown below. 
Column: Aquapore Butyl {C4) 
Mobile Phase: A: 0.1% TFA in ~o 
B: 0.08% TFA in CH3CN 
Gradient: 30-50% B, 20 minutes, linear 
Flow Rate: 0.75 ml/min 
Detection: UV, 206 nm 
Sample: 4 µg tryptase 
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peak under the specified conditions. A control experiment run 
prior to the sample revealed an identical base line. 
subsequent N-terminal amino acid sequence analysis using the 
Edman degradation method revealed a single sequence from the 
purified tryptase. 
2. Deglycosylation Of Tryptase 
An enzymatic deglycosylation reaction was performed to 
evaluate the extent and heterogeneity of glycosylation of 
tryptase. N-Glycanase (Peptide-N4-(N-acetyl-P-glucosaminyl} 
asparagine amidase} (Plumer ~ al. 1984} catalyzes the 
hydrolysis of Asn-linked oligosaccharide at the P-aspartyl-
glycosylamine bond between the innermost GlcNAc and the 
asparagine residue. The N-Glycanase releases all common 
classes of Asn-linked oligosaccharide such as high-mannose, 
complex and hybrid oligosaccharide including sialylated, 
phosphorylated, or sulfated sugar chains (Maley et al. 1989}. 
Figure 4 shows that N-Glycanase modified the properties of 
tryptase as observed by SDS-PAGE. Lane 1 is the tryptase 
treated with 1.65 units of N-Glycanase under the conditions 
described in Methods. Lane 2 is the untreated tryptase. 
Molecular weight standards are indicated in the figure. The 
untreated tryptase appeared as a broad band on the gel. This 
type of appearance is not uncommon for glycosylated proteins. 
The presence of N-Glycanase reduced the broad band to a sharp 
single band suggesting that 
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Figure 4. SOS- PAGE Of N-Glycanase Treated Tryptase. Sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SOS-PAGE) 
was performed on a Pharmacia PhastSystem. N-Glycanase-treated 
and untreated tryptase samples were separated in a 12. 5% 
homogeneous PhastGel under denaturing and reducing conditions. 
The positions of the molecular weight standards are indicated 
next to the samples. The gel was developed in silver stain. 
Lane 1 is the treated tryptase ( O. 4 µg) . Lane 2 is the 
untreated tryptase (0.4 µg). 
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Figure 5. Molecular Weight Change Following Deglycosylation. 
Tryptase was enzymatically deglycosylated by incubation with 
N-Glycanase and subjected to SDS-PAGE as shown in Figure 4. 
The molecular weight standards are shown in the open circles. 
The molecular weights of the standards on a common logarithm 
scale are plotted against the corresponding Rf values as 
defined in the text. Native tryptase and N-Glycanase treated 
tryptase samples are shown in the solid circles. The 
deglycosylated tryptase shows an apparent reduction of its 
molecular weight by about 4,000 daltons. 
O Bovine Albumin 66,000 
Ovalbumin 45,000 
Pepsin 34, 700 
Native Tryptase 
Deglycosylated Tryptase 
Trypsinogen 24,000 O 
p-Lactoglobulin 18,400 
Lysozyme 14,300 
0.4 0.6 0.8 
Rf Values 
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tryptase is glycosylated through asparagine linkages. The 
fact that tryptase was purified with a concanavalin A-agarose 
column is consistant with this observation. N-Glycanase in a 
control, which contained 1.65 units of N-Glycanase and all of 
the other reaction components except tryptase, was not 
detected under the above experimental conditions. The 
molecular weight of tryptase was reduced by about 4, 000 
daltons by N-Glycanase (Figure 5) . 
3. Alkylation And Peptide Purification 
Before fragmentation of tryptase, cystine residues of the 
enzyme were converted to stable S-carboxymethylcysteine using 
<3H)iodoacetic acid as described in Methods. Residual salts 
were removed from the alkylated protein through a Sephadex G-
25-80 column. The column was calibrated with bovine serum 
albumin (BSA) in NH4HC03 buffer. Two separate BSA samples, 5 
mg and 1 mg, were applied to the column. In both cases, the 
protein peaks fell into the same fraction numbers. Consistent 
result of the same calibration was obtained in another column 
equilibrated with formic acid. Calibration was performed 
every time prior to desalting the alkylated protein. The 
protein was very well separated from the salts in the columns 
under the conditions used. The major salt peak did not come 
out until after 16 ml of the solvents passed through the 
column as indicated by precipitation of the salt. Fractions 
were counted in a P-counter to confirm the presence of the 
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alkylated protein. A typical alkylation result is presented 
in Figure 6. The calibration curve indicated that BSA came 
out at fraction number 8 and 9. Results of radioactivity 
measurement precisely located the highest DPM values of the 
alkylated and radiolabeled tryptase in the same fraction 
numbers. 
After alkylation, the protein was subjected to enzymatic 
fragmentation. The cleavage of tryptase by enzymatic methods 
results in a mixture of peptide fragments which must be 
separated and purified before determination of their amino 
acid sequence. Analytical polyacrylamide gel electrophoresis 
was performed in 12% gel containing 8 M urea. Based on the 
results, a fractionation method was selected for separation of 
the peptides. Three surface chemistries (butyl-, octyl-, and 
octadecyl-} were used in an attempt to separate the peptides 
according to their different hydrophobicities. After 
sufficient pilot testing, larger amount of the samples was 
separated using a selected column and specific condition which 
provided the best resolution. 
Peptides from the tryptic digest were separated on a C18 
column (OD102, Rainin} . Figure 7 shows results of this 
separation. All identifiable peaks were collected in separate 
plastic tubes. The shoulder of a peak was collected in a 
separate tube to minimize any possible 
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Figure 6. Desalting Of Alkylated Tryptase On A Sephadex G-25-
80 Column. A G-25-80 Sephadex column was equilibrated in 9% 
formic acid. A typical calibration curve for 1 mg BSA is shown 
in the open circles. The absorbance values of BSA at 280 nm 
are plotted against the fraction numbers. Elution of alkylated 
tryptase is detected by the radioactivity in the fractions. 
The fraction numbers are plotted against the DPM values shown 
in the solid circles. 
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Figure 7. Tryptic Digest Of Tryptase. Rat skin tryptase 
fragments from a tryptic digest were separated by reversed-
phase HPLC using a C18 column on a Varian Model 5500 system. 
All identifiable peaks were collected in separate plastic 
tube. Peak number 19, 24, 31, and 37 were sequenced. The 
conditions of the separation were as the follows. 
Column: OD102 (Cl8) 
Mobile Phase: A: 0.1% TFA in ~o 
B: 0.08% TFA in C~CN 
Gradient: 0-60% B, 60 minutes, linear 
Flow Rate: 0.5 ml/min 
Detection: UV, 206 nm 
Samples: 20 µg tryptic peptides 
r-M 
...-4 
M
 
~
 
N
 
O
> 
...-4 ~
 
...-4 
0 co 
0 10
 
0 ~
 
0 M 
0 N 
0 
4
5
 
rn 
Q
) 
-+-> 
;:j 
~
 
•.-4
 
~
 
46 
overlap of the peaks. Peaks number 19, 24, 31, and 37 were 
successfully sequenced without further purification. 
The strategy for separation of the Lysylendopeptidase-C 
(Lys-C} digest was different. The digest was first subjected 
to gel permeation chromatography (Figure 8) to give three 
peaks containing peptides of different sizes. Peak 1 was then 
subjected to reversed-phase HPLC using a C4 column (Figure 9}. 
only one peak was observed which was subjected to amino acid 
sequence determination. 
4. Peptide Sequences 
The sequence of a total of 119 amino acids were 
determined from 6 peptides (Figure 10). Direct sequencing of 
the purified tryptase produced a sequence of 37 amino acids 
for the amino-terminus (N-T) indicating that the N-terminus is 
not blocked. The unambiguous sequence indicated that the 
tryptase was purified to homogeneity. A blank cycle appeared 
at position 21, which was followed by aspartate and threonine. 
The site for an N-glycosidic linkage has the general 
structure: Asn-(X}-Ser or Thr, where X can be a variety of 
amino acid residues. Asn provides the attachment point for a 
glycosyl chain which often contains terminal sialic acid 
residues, galactose, mannose, and N-acetylglucosamine. The 
hydrophilic glycosyl groups in the glycosylated Asn residue 
often prevent extraction of the Asn anilinothiazolinone 
derivative during Edman sequencing. 
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Figure 8. Gel Permeation Chromatography. The 
Lysylendopeptidase-C (Lys-C) digest was separated by HPLC 
using a gel permeation column. Three broad peaks are 
identified. The separation conditions are shown below. 
Column: Bio-Sil TSK-125, 60 cm L x 7.5 mm ID 
Mobile Phase: 6 M quanidine HCl 
10 mM potassium phosphate, pH 6 
Flow Rate: 0.5 ml/min 
Detection: UV, 226 nm 
Samples: Lys-C digest 
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Figure 9. Separation By C4 Reversed-Phase Column. Peak 
number 1 from the gel penneation chromatography was subjected 
to reversed-phase HPLC using a C4 column. A single peak was 
identified. The separation conditions are shown below. 
Column: BU300 {C4) 
Mobile Phase: A: o .1% TFA in ~o 
B: 0 .08% TFA in CH3CN 
Gradient: 25-50% B, 25 minutes, linear 
Flow Rate: 0.5 ml/min 
Detection: UV, 206 
Sample: peak number 1 of the Lys-C digest from gel 
permeation chromatography 
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The glycosylated residue is not normally identifiable through 
a regular sequencing procedure. The above observation 
together with the fact that the tryptase was purified from 
concanavalin A column and deglycosylated by N-Glycanase 
strongly suggest that the blank cycle could be an asparagine 
residue in the putative glycosylation site. 
The Lys-c peptide was sequenced through 23 amino acids. 
A blank cycle was also present in this peptide at the sixth 
position. 
suggests 
tryptase. 
The presence of Ile and Thr after this cycle 
the presence of another glycosylation site in 
A total of 59 amino acid residues were determined from 
peptides Try-19, Try-24, Try-31, and Try-37 from the tryptic 
digest. Peptide Try-24 has an unidentified residue. 
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Figure 10. Peptide Sequences. Purified peptides from rat 
skin tryptase were sequenced by the Edman procedure using an 
ABI 477A automated sequencer with on-line PTH analyzer 120 A. 
Sequences of six peptides are presented in the figure. N-
terminal: amino terminal sequence obtained by sequencing 
purified tryptase directly; Lys-C: the peptide of 
Lysylendopeptidase-C digest after C4 reversed-phase column 
purification; Try-19, Try-24, Try-31, and Try-37: peptides of 
the tryptic digest from peak number 19, 24, 31, and 37 after 
C18 reversed-phase column chromatography; X: blank cycle 
representing potential glycosylated Asn residue in the 
sequence; Z: undetermined amino acid residue. 
PEPTIDES SEQUENCED 
1. N-Terminal 
Ile-V al-Gly-Gly-Gln-Glu-Ala-Ser-Gly-Asn-Lys-Trp-Pro-Trp-Gln-V al-
Ser-Leu-Arg-Val-X-Asp-Thr-Tyr-Trp-Met-His-Phe-Cys-Gly-Gly-Ser-
Leu-Ile-Asn-Pro-Glu 
2. Lys-C 
Leu-Thr-Asn-Pro-Val-X-Ile-Thr-Ser-Asn-Val-His-Thr-Val-Ser-Leu-Pro-
pro-Ala-Ser-Glu-Thr-Phe 
3. Try-19 
Gly-Leu-Asn-Thr-Gly-Asp-Asn-Val-His-Ile-Val-Arg 
4. Try-24 
Val-Asp-Met-Leu-Cys-Ala-Gly-Asn-Glu-Gly-His-Asp-Ser-Cys-Z-Gly-
Asp-Ser-Gly-Gly-Pro 
5. Try-31 
V al-Thr-Tyr-Tyr-Leu-Asp 
6. Try-37 
V al-Glu-Asp-Thr-Trp-Leu-Gln-Ala-Gly-Val-V al-Ser-Trp-Gly-Glu-Gly-
Cys-Ala-Gln-Pro-Asn 
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CHAPTER V 
DISCUSSION 
partial Amino Acid Sequence Of Rat Skin Tryptase. 
The sequence of 119 amino acids determined for rat skin 
tryptase account for about 45% of the total primary sequence 
of the enzyme. Among all tryptases, rat skin tryptase is the 
first to be sequenced to this extent by the Edman procedure. 
As mentioned in the literature review section, amino acid 
sequences of other tryptases have all been derived from cDNA 
sequences. Although precise assignment of any of the amino 
acid sequences to a functionally active tryptase remains to be 
clarified, the primary sequences still provide a wealth of 
information for analysis of the potential structural 
properties of tryptases. The six peptides from rat skin 
tryptase were aligned to the corresponding regions of other 
tryptase sequences as shown in Figure 11 according to the 
alignment data generated by GCG (Devereux et al. 1984) and 
others (Johnson & Barton 1992) . Tryptase numbering system is 
used. The homology between each peptide and its corresponding 
portion in other tryptase sequences is summarized in Table 2. 
References to the tertiary structures is made based on 
computer models of serine proteases (Greer 1990) and tryptase 
(Johnson & Barton 1992). 
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Figure 11. Tryptase Sequence Alignment. Peptide sequence of 
rat skin tryptase are compared with the amino acid sequences 
of bovine trypsin and other tryptases. Sequence alignment is 
constructed based on the earlier presentation (Chen et al. 90) 
and a recent report (Johnson & Barton 92). Amino acid 
positions of tryptase are indicated beneath the first digit of 
each number. BT, bovine trypsin; HLTa, human lung tryptase a 
(Miller et al. 89} ; HLTP, human lung tryptase P (Miller et al. 
90), which is identical to human skin tryptase 2 (Vanderslice 
et al. 90); HSTl, human skin tryptase 1; HST3, human skin 
tryptase 3; DMT, dog mastocytoma tryptase (Vanderslice et al. 
89); MMCTl, mouse mast cell tryptase 1 (Chu 90); MMCT2, mouse 
mast cell tryptase 2, which is identical to mouse mast cell 
protease 6 (Reynolds et al. 91}; •, identifies the catalytic 
site histidine, aspartate, and serine; +, points to the 
substrate binding site aspartate; and *, highlights the 
putative glycosylation sites in small letters. 
BT 
HLTa 
HLT/J 
HSTl 
HST3 
DMT 
MMCTl 
MMCT2 
RST 
BT 
HLTa 
HLT/J 
HSTl 
HST3 
DMT 
MMCTl 
MMCT2 
RST 
BT 
HLTa 
HLT/J 
HSTl 
HST3 
DMT 
MMCTl 
MMCT2 
RST 
1 11 * 31 41 • 51 61 71 81 
IVGGYTCGANTVPYQVSLN SGY HFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVEGN EQFISASKSIVHPSYN 
IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGGSLIHPQWVLTAAHCLGPDVKDLATLRVN SGTHLYYQDQLLPVSRIMVHPQFY 
IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFY 
IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFY 
IVGGQEAPRSKWPWQVSLRVRDRYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFY 
IVGGREAPGSKWPWQVSLRLKGQYWRHICGGSLIHPQWVLTAAHCVGPNVVCPEEIRWQLREQHLYYQDHLLPVNRIVMHPNYY 
IVGGHEASESKWPWQVSLRFKLNYWIHFCGGSLIHPQWVLTAAHCVGPHIKSPQLFRVQLREQYLYYGDQLLSLNRIVVHPHYY 
IVGGQEAHGNKWPWQVSLRAndtYWMHFCGGSLIHPQWVLTAAHCVGPDVADPNKVRVQLRKQYLYYHDHLMTVSQIITHPDFY 
IVGGQEASGNKWPWQVSLRVxdtYWMHFCGGSLINPQ 
• * 111 121 131 141 151 161 
SNTLNNDIMLIKLKSAASLNSRVASISLPTSCA SAGTQCLISGWGNTKSS GTSYPDVLKCLDAPILSDSSCKSAYP 
IIQTGADIALLELEEPVnisSRVHTVMLPPASETFPPGMPCWVTGWGDVDNDEPLPPPFPLKQVKVPIMENHICDAKYHLGAYT 
TAQIGADIALLELEEPVKVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYT 
TAQIGADIALLELEEPVnvsSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYT 
TAQIGADIALLELEEPVnvsSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYT 
TPENGADIALLELEDPVnvsAHVQPVTLPPALQTFPTGTPCWVTGWGDVHSGTPLPPPFPLKQVKVPIVENSMCDVQYHLGLST 
TAEGGADVALLELEGPVnvsTHIHPISLPPASETFPPGTSCWVTGWGDIDNDEPLPPPYPLKQVKVPIVENSLCDRKYHTGLYT 
IVQDGADIALLKLTNPVnisDYVHPVPLPPASETFPSGTLCWVTGWGNIDNGVNLPPPFPLKEVQVPIIENHLCDLKYHKGLIT 
STNPVxitSNVHTVSLPPASETF GLNT 
171 181 • 191• * 211 221 231 241 
GQ ITSNMFCAGYLEGGKDSCQGDSGGPVVC SGK LQ GIVSWGSGCAQKNKPGVYTKVCNYVSWIKQTIASN 
GDDVRIIRDDMLCAG NSQRDSCKGDSGGPLVCKVngtWLQAGVVSWDEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP 
GDDVRIVRDDMLCAG NTRRDSCQGDSGGPLVCKVngtWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP 
GDDVRIVRDDMLCAG NTRRDSCQGDSGGPLVCKVngtWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP 
GDDVRIVRDDMLCAG NTRRDSCQGDSGGPLVCKVngtWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP 
GDGVRIVREDMLCAG NSKSDSCQGDSGGPLVCRVRGVWLQAGVVSWGEGCAQPNRPGIYTRVAYYLDWIHQYVPKEP 
GDDFPIVHDGMLCAG NTRRDSCQGDSGGPLVCKVKGTWLQAGVVSWGEGCAQPNKPGIYTRVTYYLDWIHRYVPEHS 
GDNVHIVRDDMLCAG NEGHDSCQGDSGGPLVCKVEDTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKDF 
GDNVHIVRVDMLCAG NEGHDSCZGDSGGP VEDTWLQAGVVSWGEGCAQPN VTYYLD 
U1 
O'I 
',"""'! 
N-Ter Lys-C Try-19 Try-24 Try-31 Try-37 Overall 
(37) (23) (12) (21) (6) (21) (119) 
BT 68 26 0 64 33 67 43 
HLTa 86 78 58 80 100 90 82 
HLTfl 84 70 67 80 100 90 81 
HS Tl 84 74 67 80 100 90 82 
HST3 86 74 67 80 100 90 82 
DMT 73 52 75 80 83 86 75 
MMCTl 76 61 58 75 100 90 77 
MMCT2 92 78 92 95 100 100 93 
Table 2. Peptide Sequence Homology. Peptide sequences from rat skin tryptase were 
compared with the corresponding portion of the amino acid sequence of other tryptases. 
The table gives the percentage of the identity of each peptide from rat skin tryptase to 
the corresponding regions in other tryptases. The overall identity is also indicated. 
The number of amino acids in each peptide is indicated in a parentheses. BT, bovine 
trypsin; HLTa, human lung tryptase a (Miller et al. 89); HLTfl, human lung tryptase fl 
(Miller ~ .s!l. 90), which is identical to human skin tryptase 2 (Vanderslice §t. .s!l. 90); 
HSTl, human skin tryptase 1; HST3, human skin tryptase 3; DMT, dog mastocytoma tryptase 
(Vanderslice~ al. 89); MMCTl, mouse mast cell tryptase 1 (Chu 90); MMCT2, mouse mast 
cell tryptase 2, which is identical to mouse mast cell protease 6 (Reynolds et al. 91); 
N-Ter, N-terminal amino acid sequence from rat skin tryptase; Lys-C, the peptide from 
lysylendopeptidase-C digest; Try-19, Try-24, Try-31, and Try-37, the peptides of peak 
number 19, 24, 31, and 37 respectively from the tryptic digest. 
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The structural differences between tryptases and trypsin 
has been described in a recent paper (Johnson & Barton 1992). 
The homology between tryptases and trypsin is about 49% with 
20-21 additional amino acids for tryptases. Rat skin tryptase 
peptides (Chen~ al. 1990) show a low overall identity (43%) 
to trypsin. Some regions are highly conserved among trypsin 
and tryptases. The catalytic site H44, D91, and S194 residues 
(based on tryptase numbering system) are present in all 
tryptases and trypsin. So is the substrate binding D188, 
which is characteristic of trypsin-like rather than 
chymotrypsin-like serine proteases. However, tryptase does 
show some marked differences from trypsin. The most distinct 
feature of tryptases is the two insertions on either side of 
the active site cleft compared with trypsin. There are four 
more amino acid residues in tryptase than in trypsin between 
residues 20 and 26 (Figure 11) . There is also a 9 amino acid 
insertion located between 164 and 174. Both of the insertion 
sites are involved in inhibitor binding region of serine 
protease. These two insertions may contribute to the higher 
substrate selectivity of tryptase as well as to the resistance 
of tryptase to many trypsin inhibitors. Another unique 
feature of tryptases is the extra number of tryptophan 
residues and proline patches. Tryptase has five more 
tryptophan residues than does trypsin. Three dimensional 
modeling of tryptase (Johnson & Barton 1992) based on trypsin 
structure reveals that four of the five tryptophan residues 
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not found in trypsin, W12, 14, 126, and 206, form a cluster on 
the opposite side of the active site. There is another 
hydrophobic stretch between L139 and L145 which includes the 
proline patches along one edge of the tryptase model (Johnson 
& Barton 1992) . The sequences obtained from the rat skin 
tryptase peptides account for four of the tryptophan residues 
unique to tryptase. Three of them, W12, 14, and 25, are 
located in the N-terminal peptide. The other one, W206, is 
located in the Try-37 peptide. Tryptophan, leucine, and 
proline residues in tryptase seem to have arisen from mutation 
rather than insertion. Tryptase is a tetramer. The hydrophobic 
regions may play a role in the interaction between the 
subunits. 
Tryptase is a mediator of mast cell granule and released 
together with heparin from mast cell during degranulation 
(Pearce 1989). Human lung tryptase activity is stabilized by 
heparin (Schwartz & Bradford 1986). The observations 
mentioned suggest that tryptase somehow interacts with 
heparin. Binding to heparin requires that tryptase have 
sufficient surface positive charges (Blankenship et al. 1990). 
Amino acid sequences show that tryptase has 6 more lysine and 
arginine, and 7-10 more histidine residues than trypsin does. 
These basic residues are found on the surface of the molecule 
indicating that they may play a role in heparin binding. 
Human tryptase has been shown to bind to heparin at neutral pH 
as well as at acidic pH. The pKa for histidine is 6, which 
r 
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suggest that histidine may not be an important factor for 
heparin binding at neutral pH. However, histidine may play a 
more important role in heparin binding inside mast cell 
granules which has a pH value of 5.6 {DeYong et al. 1987). 
since the pI values for lysine and arginine are 9.7 and 10.8 
respectively, they are believed to have a major role in 
extracellular tryptase binding to heparin at neutral pH. In 
spite of the potential role of the basic residues, charges 
alone should not be over emphasized. Trypsin has a net charge 
of +5 in comparison to -4 to -10 for tryptase due to more 
total acidic residues. Further evidence is needed to identify 
the heparin binding sites. Rat skin tryptase, which has an 
overall 92% homology to MMCT-2, does not show evidence of 
heparin binding in vitro {Braganza & Simmons 1991) • 
Another difference of tryptase from trypsin is that all 
tryptases identified are glycosylated, which is not the case 
in trypsin. A number of putative glycosylation sites are 
found in all tryptases in Figure 11. Enzymatic 
deglycosylation of the purified tryptases showed the molecular 
weight of tryptase shifted to a smaller size after incubation 
with deglycosylation enzymes as shown in the results above and 
else where {Cromlish et al. 1987, Braganza & Simmons 1991). 
Like other tryptases, rat skin tryptase peptides significantly 
differ from trypsin with only from O to 68% homology between 
the corresponding regions {Table 2). 
While the differences between tryptase and trypsin is 
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remarkable, the distinction among tryptases is also 
significant. Rat skin tryptase peptide sequences and other 
tryptase sequences have revealed a great extent of homology as 
well as differences. The conunon and unique functional 
properties of tryptases may be the result of the structural 
similarities and differences among them. Like other 
tryptases, rat skin tryptase peptides have revealed the 
conserved residues such as the catalytic site residue S194, 
substrate binding site residue 0188, and the tryptophan 
residues specific to tryptase but not to trypsin, W12, W14, 
W25, and W206. Residues between 0188 and C200 located next to 
the active site of serine protease are highly conserved among 
tryptases. This region show 100% amino acid identity among 
tryptases except HLT-a which has a 92% identity. The stretch 
from W206 to N222 starts from one side opposite to the active 
site, passes through the interior of the molecule, and reaches 
the region on the other side near the substrate binding site 
according to the computer models (Johnson & Barton 1992) . 
Yet, this long stretch reserves about 100% amino acid identity 
among all of the tryptases including rat skin tryptase. The 
highly homologous regions sampled above may ref le ct the 
underlying structural identity which determines the functional 
similarities among tryptases. 
The unique functional properties of tryptases may be 
related to their structural variations. Within the two 
insertions, residues 20-26 and 164-174, high degree of amino 
r 
acid variation among the tryptases is apparent. 
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In the 
insertion between residues 20 and 26 on one side of the active 
site clef, for instance, the amino acid at position 23 among 
the tryptases varies significantly. HST-1 and HLT-P have a 
hydrophobic proline residue at the position. HST-3 and HLT-a 
have basic amino acid residues, lysine and arginine instead. 
While MMCT-1 and DMT have asparagine or glutamine with an 
amide group, both RST and MMCT-2 have a more aliphatic 
threonine with a hydroxyl group. Tolerance to this type of 
mutational change would mean that the position either has 
little biological significance to the enzyme or defines 
certain functional specificity for tryptase. Location of the 
position in the inhibitor binding region tends to support the 
latter. The amino acids in the other insertion region (164-
174) also revealed some variations among tryptases from 
different species. For example, all human tryptases have 
alanine at position 166 while mouse, dog, and rat tryptases 
have leucine instead. While all the human and the dog 
tryptases have an arginine at position 173, tryptases in mouse 
and rat have either praline or histidine. Glycine 215 is a 
well documented substrate binding site residue which is 
replaced by a valine in elastase (Shotton & Watson 1970). The 
glycine residue in HLTa is replaced by an aspartate. 
Another obvious difference among the tryptases is the 
location and number of the putative glycosylation sites. All 
human tryptases have a putative glycosylation site at position 
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203 while rat, mouse, and dog tryptases do not. A highly 
conserved putative glycosylation site is located at position 
102 in all tryptases except HLT-P. Both of the two positions 
are on the opposite side of the active site according to the 
three dimensional models proposed for serine proteases (Greer 
1990) and tryptases (Johnson & Barton 1992) . Another putative 
glycosylation site which does not exist in other tryptases is 
located at position 21 in MMTC-2 and RST. This position 
appears to be in a region near the substrate binding site. 
The functional importance of the glycosylation sites in 
tryptases remain unclear. 
The results have revealed some interesting structural 
properties of tryptases. The structural characteristics of 
tryptase provide very encouraging and helpful information for 
future exploration of the structure and function relationship 
of the enzyme. 
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PART II 
RAT MAST CELL HETEROGENEITY 
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CHAPTER VI 
INTRODUCTION 
The pace of mast cell research has been exceptionally 
rapid during the past several years because of the potential 
biochemical and clinical importance. The most recent advances 
in mast cells are summarized in the review section. Mast 
cells are localized inunune cells which have been implicated in 
the pathogenesis of many human disorders. Different mast cell 
types have been described in rodent and human tissues. 
Understanding mast cell heterogeneity is very important for 
identification of the precise role of each mast cell type in 
different disease states. In rats, mature mast cells are 
grouped under two major subsets, the connective tissue mast 
cells and mucosa! mast cells, based on their dye-binding 
properties. Alcian blue identifies both the mucosa! mast cell 
type which contains chondroitin sulfate proteoglycans, and the 
connective tissue mast cell type, which contains heparin and 
chondroitin sulfate proteoglycans. Saf ranin stains 
proteoglycan and thereby selectively stains the connective 
tissue mast cell type. In general, mature cells that remain 
blue after the alcian blue/safranin double stain would belong 
to the mucosa! mast cell type; those which counterstain red 
are of the connective tissue mast cell type. However, 
immature connective tissue mast cells stain with alcian blue, 
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but poorly, if at all, with safranin. Therefore, the dye-
binding properties of mast cells have limitations as 
discriminating markers of the two mast cell types. Recently, 
mast cell granular enzymes have been used successfully as 
markers in the identification of mast cell subsets. 
Monospecif ic and monoclonal antibodies against rat mast cell 
chymase I and chymase II were used to distinguish the 
connective tissue mast cell from the mucosal mast cell type 
respectively. Anti-chymase I antibody identified connective 
tissue mast cell in skin, tongue, intestinal serosa and 
submucosa, and lung pleural membrane. Anti-chymase II 
antibody identified mucosal mast cells as the predominant type 
in mucosa of small intestine and stomach. Chymase II positive 
mast cells also were detected in other tissue locations such 
as around bronchi, thymus, liver, and submucosa of stomach. 
In humans, mast cells have also been classified based on 
their neutral protease content. One type contains only 
tryptase; the other contains tryptase, chymase, mast cell 
carboxypeptidase and a cathepsin G-like protease. Based on 
tissue distribution, the type with only tryptase corresponds 
more closely to the rat mucosal mast cell type while the other 
type corresponds more closely to the connective tissue mast 
cell type in rat. 
In the current study, rat tryptase is shown to be located 
only in a subpopulation of the safranin-positive, chymase I-
positive mast cells of the connective tissue type. The 
67 
obvious distinction of tryptase distribution in human mast 
cell population and rat mast cell population may reflect an 
interesting evolutionary aspect of the two species. 
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CHAPTER VII 
LITERATURE REVIEW 
It's been more than 100 years since mast cells were first 
described (Ehrlich 1878, Schwartz & Huff 1991}. This chapter 
is designed to briefly summarize the most recent advances in 
our knowledge about mast cells and to elicit an appreciation 
of the significance of mast cell research. 
1. Biological And Pathological Roles 
Thanks to the advance in cell biology, biochemistry, and 
molecular biology techniques, mast cell research has gained 
momentum in the past few years. Due to the large number of 
publications, it is impossible to cover all the details 
reported. In this section, the biological and pathological 
roles of mast cells are reviewed to help understand mast cells 
and their important roles in health and diseases. Mast cells 
are granulocytic immune cells that are frequently found at the 
interface of the internal and external environments. 
Degranulation occurs when mast cells are stimulated by 
antigens via IgE molecules on the cell surface (Segal .§.t. al. 
1977} or other endogenous and exogenous secretogogue such as 
hormones, neurofactors, cytokines, and physical stimuli such 
as heat, cold, or trauma (Bernstein & Lawrence 1990, Galli 
1990} . The biologically active mediators released from the 
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granules interact with the local environment in a unique way 
and facilitate the initiation of some normal or pathological 
events. 
Mast cells in the airway. The role of mast cells in 
bronchial asthma has been well established (Maron 1991, 
Schwartz & Huff 1991). Brochial asthma, a manifestation of 
immediate hypersensitivity, is a disease characterized by 
increase in responsiveness of bronchial smooth muscle, 
cellular infiltration, and glandular tissue secretion. Mast 
cells are present in abundance in bronchial and alveolar (Fox 
et al. 1981, Schulman _g_t. gl. 1982, Irani et al. 1986). 
Release of mediators from the effector cells in these 
locations can directly affect the activity of the respiratory 
tract. When challenged with endobronchial allergen (Wenzel et 
al. 1988) or oral aspirin (Basso et al. 1989), mast cell 
activation occured as indicated by elevated plasma levels of 
tryptase and histamine. In cases where airway obstruction 
occurs, mast cell activation and degranulation also occur 
(Broide ~ al. 1991, Jarjour et g],_. 1991). In allergic 
rhinitis, the immediate response correlates with mast cell 
degranulation (Sedgwick et al. 1991). Following this mast 
cell mediated immediate response, eosinophils are attracted to 
the airway and cause airway injury during the late-phase 
allergic reaction. Mast cells are also involved in 
experimentally induced nasal allergic response (Walden et al. 
1988). It was reported that mast cells participate in 
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pulmonary fibrosis when rats are challenged with bleomycin or 
asbestos (Goto et al. 1984, Wagner et al. 1984). When mast 
cells were co-cultured with fibroblast and mesothelial cells, 
two predominant and yet morphologically distinct neighboring 
cell types, and mast cell degranulation was induced by 48/80, 
subsequent induction of mitogenesis occurred in both 
fibroblasts and mesothelial cells (Druvefors & Norrby 1988). 
The observation supports the role of mast cells in fibrosis. 
However, whether the mast cells cause pulmonary fibrosis or 
result from the fibrosis remains unclear. The observation 
that pulmonary fibrosis could be induced in mast cell-
deficient mice suggested the possibility that the increase of 
mast cell number might be the result of pulmonary fibrosis 
(Mori et al. 1991). 
Mast cells in gastric system. The participation of mast 
cells in gastrointestinal infections has been documented. Mast 
cells are found in large number in intestinal mucosa (Enerback 
1966, Fox gt. al. 1985). Parasitic infection dramatically 
increases mast cell population in the mucosal area in rodents 
(Mayrhofer 1979a, 1979b, Mayrhofer & Bazin 1981, Stevens et 
al. 1986). After roundworm infection, rat mucosal mast cells 
degranulate and result in elevated levels of secreted chymase 
II (Woodbury et al. 19 84) , a serine protease which may enhance 
vascular permeability, suggesting that mast cell activity may 
play an important role in resisting parasite infection. Mast 
cells have been found to be responsible for the acute gastric 
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damage and restraint stress-induced gastric ulceration (Guth 
& Kozbur 69, Andre et al. 85, Galli et al. 85). Compound 
49/80 causes mast cell degranulation leading to severe gastric 
lesions (Franco ~ gl. 1959, Cho _g.t_ al. 1979, Ogle gt. al. 
1980, Takeuchi et al. 1986). Ethanol is known to cause mast 
cell-dependent augmentation of acute gastric mucosal damage 
(Wallace et gl. 1982, Galli et al. 1985). Sodium cromoglycate 
and FPL-52694 are agents known to inhibit mast cell 
degranulation and are called mast cell stabilizers (Takeuchi 
et al. 84, Goossens~ al. 1987). These agents have been 
shown to inhibit gastric damage resulting from changes in acid 
secretion and gastric motility induced by compound 48/80, 
ethanol, restraint stress and other compounds which cause mast 
cell degranulation (Ogle & Lau 1980, Canfield & CUrwain 1983, 
Takeuchi et al. 1984, Takeuchi ~ al. 1986, Goossens et al. 
1987, Wallace et al. 1988, Beck et al. 1989). In rats 
pretreated with the two mast cell stabilizers, the number of 
mast cells were significantly reduced in the ethanol treated 
rats. Correspondingly, both agents significantly reduced 
ethanol- induced damage in a dose dependent manner (Beck et al. 
1989). 
Mast cells and tumors. There is an increasing amount of 
evidence for mast cell interaction with tumor cells (Hartveit 
1981, Hartveit et al. 1984, Parwaresch et al. 1985, Ionov 
1989, Flynn et al 1991). Mast cells have been found at tumor 
sites (Dabbous 1980, Van den Hooff et gl. 1983, Woolley 1984, 
Roche 19 85) . 
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Degranulation of mast cells at these sites 
suggests that mast cell-tumor cell interactions might enhance 
invasive growth of human and animal tumors (Csaba §..t. al. 1961, 
Hartveit & Sandstad 1982, Farnoush & Mckensie 1983, Norrby & 
Enstrom 1984) . Previous studies had shown that extensive 
extracellular matrix degradation was associated with tumor 
invasion and metastasis (Yamanishi et al. 1972, Hashimoto et 
al. 1973, Liotta ~ gl. 1980). In terms of release of 
collagenolytic activity, tumor-derived fibroblast-like cells 
appeared to be more responsive to mast cell products than did 
normal fibroblasts (Dabbous et al. 1986) . The mast cell 
factors responsible for stimulating collagenolytic activity 
were apparently not histamine or heparin. In more recent 
studies (Gruber et gl. 1988, 1989), tryptase was shown to have 
a potential role in matrix degradation via activation of 
prostromelysin to stromelysin which in turn degrades 
extracellular 
collagenase. 
matrix components and activates latent 
Studies using mast cell-stabilizing compounds 
provided support for mast cell involvement in tumor metastasis 
(Dabbous et al. 1991). Rat pretreated with FPL 55618 which 
prevents mast cell degranulation, caused a 70% inhibition of 
tumor growth at the primary site. After 23 days without 
treatment, tumor growth of the rats accelerated and reached a 
similar tumor size to that of control animals. Numerous mast 
cells were detected around the tumor periphery and often 
showed signs of degranulation. In contrast to the untreated 
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animals, FPL 55618 treated animals showed numerous intact mast 
cells within the tumor mass. In contrast to in vivo 
experiments, FPL 55618 had no direct effect on the rate of rat 
mammary adenocarcinoma proliferation in vitro. Soluble mast 
cell product, on the other hand, significantly increased the 
rate of tumor cell proliferation. These observations 
demonstrated the potential importance of mast cell and tumor 
cell interaction in the growth and invasive properties of 
tumor cells in vivo. In IgE-dependent mast cell activation, 
the inunediate release of preformed mast cell mediators is 
followed by synthesis and sustained release of large 
quantities of newly formed tumor necrosis factor alpha (Gordon 
& Galli 1991) . Ma.st cells have been implicated in 
angiogenesis in tumor sites (Messler et al. 1976, Fraser & 
Simpson 1983, Starkey et al 1988, Crowle & Starkey 1989) . 
Tumor necrosis factor is mitogenic for fibroblasts (Dayer et 
al. 1985, Young et g!. 1987) and capable of stimulating 
angiogenesis in vivo (Kessler et al. 1976, Frater-Schroder et 
al. 1987, Leibovish ~ al. 1987). Fibroblast can in turn 
influence mast cell differentiation (Levi-Schaffer et al. 
1986) and granule maturation (Davidson ~ al. 1983). Ma.st 
cell granules can actually be transferred into fibroblasts via 
phagocytosis (Nicolson 1984, Norrby & Enstrom 1984) and 
transgranulation (Greenberg & Burnstock 1983), a process in 
which mast cells establish a special cell contact with other 
cell types and release its granule into the contact cell. The 
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specific role of mast cells in tumor growth and metastasis 
remain an interesting area of investigation. 
Mast cells and the nervous system. Interaction of mast 
cells with the nervous system has been widely reported (Olsson 
1968, Ibrahim 1974, Dropp 1976, Theoharides 1990, Johnson & 
Krenger 1992). In the brain, greater than 98% of the mast 
cells are located in the thalamus (Goldsehmidt et al. 1984). 
The connective tissue coverings of the central nervous system 
are also rich in mast cells (Orr 1988, Ferrante et al. 1990, 
Dimlich gt. al. 1991). In the peripheral nervous system, mast 
cells are located in the autonomic nerve endings in tissues 
such as skin (Heine & Forster 1975, Alving et al. 1991), 
thymus and spleen (Williams & Felten 81, Weihe et al. 1989, 
Muller & Weihe 1991), intestine (Newson et al. 1983, Stead et 
al. 1987, Stead et al. 1989), mesentery (Skofitsch et al. 
1985), and lung (Bienenstock et al. 1988, Alving et al. 1991). 
Several studies have suggested that mast cells and 
nervous tissues may interact with each other bidirectionally 
(Barrett 1991) . There is evidence that the nervous system can 
influence the growth, differentiation, and degranulation of 
mast cells. When co-cultured with mast cells, glial cells 
show its ability to support mast cell growth in vitro 
(Seeldrayer ~ .sU:,. 1989, Ryan & Huff 1990). The glial cells 
are known to secrete nerve growth factor (Lindholm et al. 
1987, Houlgatte ~ al. 1989} which can affect mast cell 
development. In cell culture, addition of nerve growth factor 
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increases the number and size of mast cells (Aloe 1977, 1988). 
When spleen cells pretreated with nerve growth factor were 
injected into the brains of developing rats, the cells 
differentiated into mast cells (Aloe & DeSinone 1989). While 
the ability of noradrenaline and acetylcholine to stimulate 
mast cell degranulation is still controversial (Manunaioini et 
al. 1975, Fantozzi gt. Sil. 1978, Kazimierczak et al. 1980, Alm 
& Bloom 1981, Masini et al. 1985, Botana et al. 1987), many 
neuropeptides have been shown to activate mast cells. 
Somatostatin induces degranulation of rat peritoneal mast 
cells and human skin mast cells (Theoharides et al. 1978, 
1980, Piotrowski & Foreman 1985, Renold et al. 1987). 
Substance P (Erjavec gt. Sil. 1981, Fewtrell et al. 1982, 
Shibata et al. 1985, Ebertz et al. 1987), endorphins (Yawasaki 
et al. 1982, Shanahan et al. 1984), neurotensin (Lazarus et 
al. 1977, Sydbom 1982), opioid peptides (Casale et al. 1984), 
vasoactive intestinal peptide (Piotrouski & Foreman 1985), 
calcitonin gene-related peptide (Fremann 1987), neurokinin 
(Wallengren & Hakanson 1987) , prostaglandin D2 (Levi-Schaffer 
& Shalit 1989), and neuropeptide Y (Arzubiaga et al. 1991) are 
all capable of causing mast cell degranulation, perhaps 
through the P-adrenergic receptors (Marquarett & Wasserman 
1982, Lowman~ al. 1988, Arbabian gt. al. 1989) and muscarinic 
cholinergic receptor (Masini ~ al. 1983) on the surface of 
mast cells. 
Mast cells can also influence nervous tissue. Histamine, 
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a mast cell mediator, is a neurotransmitter capable of 
regulating synaptic transmission (Steinbusch & Muller 1984, 
Villena et al. 1986, Weinreich & Undem 1987, Christian et al. 
1989, Wada tt gl. 1991) and inducing electrophysiological 
changes in vitro (Green et al. 1988, Janiszewski et al. 1990). 
rromunological regulation of synaptic transmission has been 
observed in isolated guinea pig autonomic ganglia (Weinreich 
~ al. 1987) and in patients with allergic disease (Casale 
1983). Mast cells can affect the content of 5-
hydroxytryptamine, a neurotransmitter, in rodent sensory 
ganglia (Kai & Keen 1985), and rat intestinal motor (Bueno tt 
al. 1991). Serotonin, vasoactive intestinal peptide, and 
somatostatin-like molecules secreted by mast cells of brain 
and other tissues may also modulate the neural activities in 
the nervous system (CUtz et s.l. 1978, Goetzl tt al. 1985, 
Lambracht-Hall tt al. 1990). 
Besides serving as sources of neurotransmitters, mast 
cells can also regulate local neuronal activities through 
modification or processing of other neural peptides by mast 
cell neutral proteases. As mentioned earlier, tryptase 
selectively hydrolyzes potent bronchodilators such as VIP, 
PHM, and CGRP but not the bronchoconstrictor SP. 
Although the mechanism of mast cell/nervous 
interaction has not been resolved (Marshall et s.l. 
system 
1989, 
Bienenstock et gl. 1991) , evidence for such interactions have 
been uncovered in many neural disorders such as CNS 
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inflammatory demyelination {Mokhtarian & Griffin 1984, Griffin 
& Mendoza 1986), systemic mastocytosis {Rogers et al. 1986, 
Iriarte et al. 1988, Schwartz~ gl. 1987), neurofibromatosis 
{Isaacson 1976, Riccardi & Eichner 1986, Claman 1987, Riccardi 
1987, Johnson~ gl. 1989, Riccardi, 1989), and in peripheral 
nerve disease {Barnes et al. 1990, Kiernan 1990). For 
example, increased mast cell degranulation was detected in 
experimental allergic encephalomyelitis {EAE), a model of CNS 
demyelination {Bo ~ gl. 1990, Krenger et al. 1991). Mast 
cell degranulation was also observed in experimental allergic 
neuritis {Powell et al. 1983, Izumo et al. 1985, Seeldrayers 
~ al. 1989). The precise role of mast cell in these 
disorders remain to be defined. 
Mast cells in the cardiovascular system. Involvement of 
mast cells in the cardiovascular system has gained increasing 
attention in the past several years. The role of mast cells in 
atherogenesis {Kovanen 1991) and angiogenesis {Rakusan et al. 
1990) have been investigated. The molecular events in 
coronary atherosclerosis are characterized by the local 
accumulation of LDL-derived cholesterol in the coronary 
intima, the innermost layer of the arterial wall {Smith 1974, 
Richardson ~ al. 1989, Movanen 1990). In the early stage, 
macrophages in the intima absorb cholesterol from modified LDL 
and become foam cells filled with cholesterol ester droplets 
{Fogelman et al. 1988, Hoff et al. 1990). Cholesterol can 
accumulate in the foam cells and then extend from its 
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intracellular position to form a soft extracellular 
cholesterol core (Smith 1974, Guyton g.t. al. 1990) which 
develops into atherosclerotic lesions (McGill 1968, Stary 
1987, Stehbens 1987) • However, studies have shown that 
macrophages do not endocytose LDL unless the LDL molecules are 
first modified (Goldstein et al. 1979, Steinberg et al. 1989), 
a process which may involve mast cells. 
Mast cells have been detected in the arterial intima 
(Pollak 1957, Pouchlev ~al. 1966, Kamio et al. 1979). An 
extensive autopsy study of human from birth to age 39 showed 
that twice as many mast cells were present in the arterial 
intima of both early and advanced atherosclerotic lesions 
compared to non-disease intima (Stary 1990) . The role of mast 
cells in atherosclerosis has been proposed based on both in 
vitro and in vivo experimental results. After degranulation 
of mast cells, heparin released from the granules binds to the 
positively charged domains of apolipoprotein B and E on LDL 
(Kokkonen & Kovanen 1987a, 1989, Kovanen & Kokkonen 1991). 
Mast cell granular proteases, mainly chymase and 
carboxypeptidase A, degrade the apolipoproteins on the LDL 
surface (Kokkonen & Kovanen 1985, Kokkonen et al. 1986). This 
results in modified LDL molecules binding to the mast cell 
granule remnant which are ultimately phagocytosed by 
macrophages located nearby (Lindahl gt. gl. 1979, Baggiolini g.t. 
al. 1982, Kokkonen & Kovanen 1987b, Lindstedt ~ al. 1992). 
Under normal circumstances, prevention of cholesterol 
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accumulation in arterial intima can be facilitated by high 
density lipoprotein (HDL) (Kovanen 1990). When mast cells are 
activated, however, HDL molecules are also modified by mast 
cell mediators and are then unable to remove cholesterol from 
the foam cells (Kovanen 1991) . Mast cells have been 
implicated in cardiac hypertrophy (Rakusan et al. 1990). A 
significantly higher percentage of mast cells was found close 
to arteriolar portions of coronary capillaries than one would 
expect from their even distribution along the capillary wall. 
The increase in cardiac mass and formation of new capillaries 
in hypertrophic rat hearts induced by pressure overload is 
accompanied by increasing number of mast cells (Rakusan & 
Campbell 1991) . 
Mast cells in other diseases. Involvement of mast cells 
in arthritis has been described extensively (Mican et al. 
1990, Gruber 1991). The number of mast cells are greatly 
increased in synovial tissue of patients with rheumatoid 
arthritis (Crisp .e.t. 2],,. 1984, Godfreg .e.t. al. 1984, Irani .e.t. 
al. 1987, Bridge et al. 1991) and in rat adjuvant arthritis 
(Gryfe et al. 1971). In one study, the severity of antigen-
induced arthritis following adjuvant injection was compared in 
mast-cell deficient mice and normal mice with mast cells 
(Ma.lone et al.. 1988, Van den Broek et al. 1988). The results 
indicated that mast cells can dictate the acute inflammatory 
events and potentiate chronic changes of cartilage 
degradation. When purified arthritogenic peptide was injected 
80 
into rat knee, acute mast cell degranulation occurred 
(Caulfield ~ al. 1988). The event was followed by 
inflammation, fat necrosis, and fibrin deposition. Tryptase 
released f ram mast cell granules may play an important role on 
chemotaxis, cartilage and bone turnover, and synovial 
fibrosis. 
The importance of mast cells in skin has been well 
recognized (Lawrence~ gl. 1987, Lowman gt. al. 1988, Rothe et 
.eJ... 1990, Church~ al. 1991, Tainsh gt. al. 1991). Increased 
number of mast cells have been observed in the pathogenesis of 
many skin disorders such as atopic dermatitis (Mihm et al. --
1976) I scleroderma (Nishioka et al. 1987), progressive 
sclerosis (Hawkins gt. al. 1985), neurofibromatosis (Isaasson 
1976, Riccardi 1981, 1987), bullous pemphigoid (Wintroub ~ 
al. 1978), abnormal wound healing such as keloid and 
hypertrophic scar (Smith et al. 1987), striae distensea (Sheu 
et al. 1991), and urticaria (Schwartz 1991). The pathways in 
f ibrotic disorders may rely on the interaction between mast 
cells and fibroblasts. One possible cause of the fibrotic 
disease is the increase in collagen synthesis by fibroblasts 
(Botstein gt. al. 1982). Initially, factors secreted by T 
lymphocytes such as IL-3 can induce the growth and 
differentiation of immature mast cells from bone marrow cells. 
However, the progress from the immature cells to mast cell-
conunitted progenitors depends on stem cell factors produced by 
fibroblasts (Ashman~ Sil. 1991). Mast cells in turn can 
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affect the growth of fibroblasts. Co-culture of bone marrow-
derived mast cells with mouse 3T3 fibroblasts resulted in the 
108s of the fibroblast contact inhibition (Dayton et gl. 
1989) . Tryptase was shown to enhance proliferation of rat and 
hamster-derived fibroblasts (Ruess et gl. 1991) . The action 
of mast cells was linked to macrophage, T cells, endothelial 
cells, and platelet (Claman 1989). In lesions of early striae 
distensae during puberty, sequential changes of elastolysis is 
accompanied by mast cell degranulation, followed by an influx 
of activated macrophages, which endocytose the fragmented 
elastic fibers (Sheu ~ al. 1991) . Mast cells are present 
in ovary (Jones et al. 1980, Krishna & Terranova 1985, 
Shinohara et al. 1987, Schmidt et al. 1988, Drishna & 
Terranova 1991), uterus (Massey et gl. 1991, Tainsh gt. al. 
1991), and placenta (Purcell & Hanahoe 1991). Variations in 
the number and extent of degranulation of mast cells in ovary 
have been shown to correspond to the oestrous cycle (Schmidt 
et al. 1988, Krishna & Terranova 1991). Uterine mast cells 
show a significant negative correlation with years of post-
menopause (Drudy et al. 1991). The functional response of 
uterine mast cells to an embryo-derived histamine releasing 
factor led to the proposal of a possible role of mast cell in 
embryo implantation and menstruation (Finn 1986, Cocchiara et 
al. 1988). Mast cells in the proximity of placenta also led 
to speculation about their involvement in pathological process 
during pregnancy and parturition (Purcell & Hanahoe 91) . 
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Mast cells were identified in the arterial wall of rat 
adrenal gland and found to modulate both vascular and 
secretory responses in the intact adrenal gland (Hinson et 2J,.. 
1988) . Adrenocorticotropic hormone (ACTH) is known to 
increase steroidogenesis and cause vasodilation in adrenal 
gland. It has been demonstrated that ACTH stimulates adrenal 
blood flow and corticosterone secrection by its action on mast 
cells (Hinson .§..t. 2J,.. 1991) . 
In the eye, mast cells found in the conjunctiva were 
found to be responsible for ocular anaphylaxis (Allansmith et 
al. 1981, 1985, 1989). 
Oral erythema multiform is usually caused by Herpes 
simplex virus or various drugs. A recent study revealed that 
mast cell numbers in the oral mucosa of patients with erythema 
multiform lesions were higher than those in the control 
subjects, suggesting that mast cell degranulation occurs in 
the most intensely inflamed area (Ruokonen 1992). 
Participation of mast cells in other oral diseases is also 
reflected by the increase in mast cells in oral lichen planus 
(Jontell et 2J,.. 1986) and gingivitis (Zachrisson 1968). 
Tobacco smoke has been shown to cause release of preformed 
mediators from canine mast cells (Thomas et al. 992). --
An increase in renal tissue mast cell number was detected 
in fulminant hepatitis patients with hepato-renal syndrome 
(Yoshimura & Mori 1991) . This suggests a role for renal 
tissue mast cells in the onset of acute renal failure in liver 
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diseases. The role of mast cell in systemic anaphylaxis and 
mastocytosis is well documented (Schwartz .et. al. 1987). 
Elevation of mast cell activation correlates with the severity 
of anaphylaxis (Matsson ~ gl. 1991, Yunginger .et. gl. 1991, 
van der Linden gt. gl. 1992). In systemic mastocytosis, liver, 
spleen, and lymph nodes may be infiltrated by mast cells and 
lead to hepatosplenomegaly and enlarged lymph nodes (Metcalfe 
1991) . Extensive involvement of mast cells may result in 
liver fibrosis, portal hypertension, and abdominal ascites. In 
vitro studies showed that mast cells enhanced the spontaneous 
and T-mitogen-induced proliferation of spleen and lymph node 
cells (Gushchin et al. 1991). 
The involvement of mast cells in the various biological 
and pathological situations reviewed above has revealed the 
functional significance of mast cells in health and disease. 
Investigation of the specific roles of different mast cell 
sub-types, although in its juvenile stage, has been considered 
very important in the search for more definite answers to the 
questions that remain. 
2. Mediators 
Understanding the mechanism of mast cell action and mast 
cell heterogeneity relies, to a great extend, on the knowledge 
of mast cell granular mediators. Mast cell mediators are 
generally divided in two groups, preformed mediators and newly 
generated mediators (Bernstein & Lawrence 1990, Gordon .et, al. 
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1990, Schwartz & Huff 1991). The following table lists the 
major mediators present in mast cell granules. 
Preformed 
Histamine 
5-HT 
Dopamine 
Heparin 
Condroitin sulfate 
Tryptase 
Chymase 
Cathepsin G 
Carboxypeptidase 
VIP 
SLM 
Newly Formed 
PGD2 
Thromboxane 
LTB4 
LTC4 
LTD4 
LTE4 
PAF 
Cytokines 
TNF-c:Y 
IL-1,2,3,4,5,6,10 
MIP-la 
MIP-lfJ 
MCAF 
TCA3 
GM-CSF 
TGF-fJ 
IF-y 
SCF 
Abbreviations used above are: 5-hydroxytryptamine (5-HT); 
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vasoactive intestinal peptide (VIP); somatostatin-like 
molecules (SLM); prostaglandin D2 (PGD2); leukotrienes (LT); 
tumor necrosis factor O! (TNF-0!); Interleukins (IL) ; macrophage 
inflanunatory proteins (MIP); monocyte chemotactic and 
activating factor (MCAF); granulocyte/macrophage-colony 
stimulating factor (GM-CSF); transforming growth factor (TGF); 
interferon (IF); stem cell factor (SCF); platelet activating 
factor (PAF) . 
Biogenic amines such as histamine, serotonin, and 
dopamine can be secreted from mast cells (Enerback 1966, 
Jenkinson ,gt. al. 1970, Weitzman et al. 1985, Larnbracht et al. 
1990) . Histamine in lung serves as a potent spasmogen which 
can cause bronchoconstriction and vasoconstriction. As a 
vasodilator in affecting local vascular permeability, 
histamine must act via the interaction with cell-specific 
receptors Hl and H2 (Schwartz 1991) . 
Mast cell proteoglycans includes highly sulfated heparin 
and less sulfated condroitin (Stevens et al. 1988, Thompson ,gt. 
al. 1988). When degranulation occurs, the proteoglycans are 
released together with granular enzymes. Heparin and 
chondroitin have a stabilizing effect on these enzyme 
activities (Schwartz & Bradford 1986, Alter et al. 1987) and 
on growth factor activities (Kellen & Lindahl 1991, Ruoslahti 
& Yamaguchi 1991) . Heparin also has well known anticoagulant 
activity (Metcalfe et al. 1981). Mast cell proteoglycans may 
play an important role in initiating binding of LDL and HDL 
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molecules in atherosclerosis (Kovanen 1991) . 
Tryptase and chymase are neutral serine proteases unique 
to mast cells (Schwartz 1990). The possible roles of tryptase 
are discussed above. Chymase converts angiotensin I to 
angiotensin II at a rate 4 times faster than does angiotensin-
converting enzyme (Wintroub ~al. 1984). Other postulated 
roles for chymases include involvement in basement membrane 
degradation (Briggaman et al. 1984), glandular mucus 
production (Sonunerhoff ru;. li- 1989) , and bradykinin 
degradation (Reilly et al. 1982). Cathepsin G is a neutral 
serine endopeptidase found in neutrophils and monocytes. A 
cathepsin G-like protease has also been found using 
inununocytochemical and enzyme histochemical techniques in mast 
cells (Schechter~ al. 1990). Carboxypeptidase A is also 
localized in mast cell secretory granules (Goldstein et al. 
1989). This enzyme preferentially removes amino acids from 
the C-terminus of peptides which have terminal aromatic 
residues or leucine. Rat mast cell carboxypeptidase A is 
similar to bovine pancreatic carboxypeptidase A (Everitt et 
al. 1980, Schwartz et al. 1982). As discussed previously, 
mast cells also contain preformed peptides such as VIP (Cutz 
et al. 1978), and SLM (Goetzl ~ ll· 1985). 
Newly formed mast cell mediators include various 
cytokines (Gorden et al. 1990), and arachidonic acid 
metabolites (Peters et al. 1984). Since the discovery of IL-4 
and TNF-a in mast cells (Brown _gt. g],_. 1987, Young et ll· 
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19 97) , many cytokines have been found in activated mast cells. 
These include IL-1, IL-3, and IL-6. Transcripts for IL-2, IL-
5, IL-10, MIPS, MCAF, GM-CSF, TGF-P, IFy, and SCF are also 
found in the activated mast cells. Many of the cytokines can 
affect mast cell growth and development. IL-3, for instance, 
can stimulate IL-3 dependent progenitors derived from bone 
marrow to progress to mast cell-committed progenitors (Huff & 
Justus 1988) . These progenitors then migrate to fibroblast-
rich sites possibly by binding to laminin through their cell 
surface laminin receptors (Thompson et al. 1989) . SCF, on the 
other hand, can directly stimulate proliferation of the 
cormnitted progenitors and induce granulation of mast cells 
(Tsai ~ al. 1991) . IL-4, and IL-10 are co-factors for 
proliferation and differentiation of mast cells (Hamaguchi et 
al. 1987, Gordon ~ al. 1990) . In contrast to the other 
cytokines, GM-CSF and IFy can suppress proliferation of mast 
cells (Bressler et al. 1989, Burd et al. 1989). The 
biological significance of some mast cells' ability to release 
both negative and positive effectors remains unclear. 
Mast cells can incorporate exogenous arachidonic acid 
into neutral lipids and phospholipids and store these lipids 
in membranes and cytoplasmic lipid bodies (Dvorak il al. 1983, 
Peters ~ ~- 1984) . When mast cells are activated, 
arachidonic acid is release from the lipids and metabolized to 
PGD2 and thromboxanes through the cyclooxygenase pathway or to 
leukotrienes and lipoxins through the lipoxygenase pathways 
(Schwartz 1987, Serofim & Austin 1987). 
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PGD2 is a 
vasoconstrictor which is released from not only mast cells 
(Robinson 1988) but also macrophages (MacDermot et al. 1984), 
platelet (Oelz et al. 1977), and CNS neurons to promote sleep 
(Hayaishi 1991). LTB4 is a potent chemotactic factor for 
neutrophils, eosinophils, monocytes, and basophils. Its 
ability to attract neutrophils is as strong as complement CSa 
(Ford-Hutchinson et slJ... 1980). LTC4, LTD4, and LTE4 are 
bronchoconstrictors and vasoconstrictors. In lung where there 
are few LTC4 receptors, LTC4 must be converted to LTD4 and 
LTE4 to mediate its effects on bronchoconstriction. LTD4-
receptor antagonists have been shown to attenuate allergic-
induced bronchoconstriction (Griffen §.t. al. 1983). PAF, a 
phosphotidylcholine analog, can cause aggregation of platelets 
and dilation of blood vessels (Kerdel & Soter 1989). 
3. Mast Cell Heterogeneity 
Mast cell are not a homogeneous cell population. The 
heterogeneity of mast cells is reflected by their responses to 
different stimuli, the content of secretory granules, and 
their phenotypes. 
Responses to stimuli. Mast cells from different 
sources were found to have different functional responses to 
IL-3. The growth and differentiation of mast cells from 
intestinal mucosa depend on IL-3 while those from connective 
tissues are mostly independent of Il-3 (Razin ~al. 1984). 
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aowever, the dependency of mast cells on IL-3 depends on the 
microenvironment and is interchangeable (Valent ~ gl. 1991) . 
When IL-3 dependent mouse mast cells were co-cultured with 
fibroblasts, they exhibited a phenotypic change toward IL-3-
independent mast cells (Levi-Schaffer~ al. 1986). Data for 
different responses of MCr (human mast cells containing 
tryptase only) and MCrc (human mast cells containing both 
tryptase and chymase) to cytokines were derived from tissue 
culture and in vivo observations. When cord blood mononuclear 
cells are co-cultured with mouse 3T3 fibroblasts, about 80-90% 
of the resulting mast cells are the MCTc phenotype (Furitsu et 
al. 1989) . It has been known that SCF secreted from 
fibroblasts can stimulate development and growth of rodent 
connective tissue mast cells (C™C) . Addition of T lymphocyte 
factors to the culture did not alter the result of MCTc cells. 
In rodent cell culture, T lymphocyte factors can reverse the 
C™C type to mucosal mast cells (MMC) . These observations 
suggest that, like rodent C™C, human MCTc type is not T 
lymphocyte dependent. 
Mast cells from different sources often respond 
differently to specific agents. Secretogogues such as the 
calcium ionophore A23187, 48/80, basic peptides (polylysine, 
polyarginine), VIP, SP, somatostatin, bradykinin, endorphins, 
morphine sulfate, and anaphylatoxin csa can stimulate 
degranulation of IL-3-independent mast cells while IL-3-
dependent mast cells such as those isolated from human lung 
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respond to A23187 but none of the others {Church~ gJ._. 1982, 
aernstein & Lawrence 1990). Disodium cromoglycate which is 
widely used for treatment of allergic asthma can inhibit 
degranulation of mast cells from human intestinal lung mucosa 
{Flint gt_ al. 1985, Schmulzler et al. 1985, Befus et al. 1987) 
but can not inhibit degranulation of mast cells from human 
skin (Cl~ggs et al. 1985). In contrast to human, disodium 
cromoglycate induces degranulation of connective mast cells 
but not mucosa! mast cells in rodent {Pearce 1986, Breninstock 
1988) . Mast cells from different sources respond to nerve 
growth factor {NGF) differently. Proliferation and 
differentiation of rat mast cells from cultured blood cells 
and spleen cells were enhanced by NGF {Aloe 1977, 1988, Aloe 
& Desimone 1989). Mucosa! mast cells, on the other hand, did 
not respond to NGF {Johnson & Krenger 1992). Mast cells in 
the gut appear to be ready to defend against parasitic 
infection {Stead~ gJ._. 1987, Arizono et al. 1990). When 
brain tissues were infected by the larval stage of the cestode 
taenia solium, brain mast cell numbers did not increase as the 
gut mast cells had {Johnson & Krenger 1992). 
Differences in mediator content. The mediator content 
of mast cells also reflects mast cell heterogeneity. 
Heterogeneity of proteoglycan content has long been recognized 
in different mast cells. Heparin has been found predominantly 
in connective tissue mast cells {Yurt ~ al. 1977) while 
condroitin E has been found mainly in mucosal mast cells 
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(Eliakim ~ g].,. 1986, Gilead et al. 1987). The distribution 
of chymase and tryptase varies depending on mast cell type and 
species (Schwartz et al. 1981a, Woodbury & Miller 1982, Irani 
~ al. 1986) . Carboxypeptidase A has been found in both human 
skin and human lung mast cells (Goldstein et al. 1989, 
Reynolds et g].,. 1989) but occurs only in CTMC in the rat 
(Everitt ~ .e.i.. 1980, Schwartz ~ al. 1982). Production of 
eicosanoids also reflects mast cell heterogeneity (Kewus ~ 
al. 1982, Heavey ~al. 1988, Church et al. 1989, Robinson et 
al. 1989). PGD2 is produced predominantly by rat peritoneal 
mast cells but is consistently produced by both human skin and 
lung mast cells. LTC4 and LTB4 are produced at a level 
significantly higher in mucosal mast cells than in connective 
tissue mast cells in the rat. Human lung mast cells produce 
approximately nine times more leukotrienes than do skin mast 
cells. The leukotrienes are mainly LTD4 and LTE 4 in human 
lung mast cells as opposed to LTC4 in skin mast cells. 
Serotonin is present in mouse peritoneal mast cells (Weitzman 
et al. 1985) and brain mast cells (Lambracht et al. 1990) but 
not intestinal mast cells (Enerback 1966) . Dopamine has been 
found in bovine skin mast cells (Jenkinson ~ al. 1970) . 
Protease contents of the two mast cell types are also 
different. Cathepsin G, for example, was detected in CMrc but 
not in MCr using immunoassay techniques (Meier et al. 1985). 
Carboxypeptidase was found at high concentration in MCrc type 
from human skin mast cells but in negligible amounts in MCT 
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type from lung mast cells based on the activity of enzymatic 
hydrolysis of angiotensin (Goldstein ~ al. 1987). 
Different phenotypes. Besides differences in stimuli 
response and mediator content discussed above, mast cells 
exhibit additional phenotypic heterogeneity (Galli 1990) . 
Mast cells have been found in different species such as in 
human, other manunals, fish and amphibians (Michels 1963) . 
Marked morphological differences exist between mast cells from 
different species as well as between mast cells in different 
anatomical locations within a species. The differences are 
defined based the properties of histochemical stains which 
discriminate mucosal type mast cell from connectives tissue 
type mast cells (Enerback 1966). In the rodent, mucosal type 
mast cells tend to be smaller and contain fewer granules than 
connective tissue type mast cells (Gleich et al. 1986). In 
the human, mast cells have subpopulations comparable, but less 
well defined, than rodent connective tissue type mast cells 
and mucosal type mast cells (Otsuka et al. 1985, Eliakim gt 
al. 1986) . Ultrastructural evidence from cytoplasmic granules 
reveal striking characteristics unique to either the human MCr 
or the MCrc (Craig et al. 1988, 1989, Dvorak et al. 1989). 
Under the electronmicroscope, mast cell cytoplasmic granules 
exhibit a variety of substructural patterns termed scrolls and 
crystals (or lattice features) . Mast cell granules from human 
lung are more uniform in shape and have lattice features. 
Human skin mast cell granules, on the other hand, have a less 
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well defined shape and show discrete scrolls. 
rmmunoelectronmicroscopic analysis indicate that the scroll 
feature is characteristic of MCr mast cells which contains 
only tryptase while the lattice or grating feature is 
characteristic of MCrc type mast cells which contain both 
tryptase and chymase. Unlike human mast cell granules which 
have intricate lamellae and scroll work, rodent mast cell 
granules show a more amorphous appearance under the electron 
microscope (Dvorak ~ al. 1983). 
Data on morphology, responses to specific stimuli, and 
mediator content reveal a marked degree of diversity in mast 
cell populations,. Various mechanisms have been proposed to 
account for mast cell heterogeneity (Galli 1990). The 
mechanisms of cellular maturation and differentiation, changes 
associated with functional activation, and acquisition of 
molecules derived from other cell types may contribute to 
phenotypic heterogeneity of mast cells by acting alone or in 
combination with the other mechanisms. Whatever the 
mechanisms, the demonstration of different mast cell 
subpopulations continue to elicit great interest due to its 
clinical significance. 
4. Classification Of Mast Cells 
Histochemistry Methods. Heterogeneity of mast cells 
poses the need for meaningful and reliable methods to identify 
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distinct subsets of mast cells which may have functional 
differences. As discussed above, mast cells are defined based 
on their content of large, electron-dense cytoplasmic granules 
made up of sulfated proteoglycans and other mediators. 
Mediators are part of the electron-dense granules of mast 
cells. However, many of the mediators are not unique to mast 
cells and are not considered proper markers for mast cells. 
Prostaglandin, thromboxanes, leukotrienes, and a varieties of 
cytokines can be products of other cell types. So can the 
biogenic amines and neuropeptides. Cathepsin G can be found 
in neutrophil and monocytes while carboxypeptidase A can be 
found in other cell types in the pancreas. The mediators 
unique to mast cells granules are tryptase and chymase. 
Proteoglycans are also part of the electron-dense 
granules which consist of many glycoaminoglycans, a chain of 
disaccharide repeating units containing an amino sugar 
derivative such as glucoamine or galactoamine, covalently 
linked to a core protein. The intracellular proteoglycans 
found in mast cell granules contain the highly sulfated 
heparin and/or the less sulfated condroitin sulfate E (Stevens 
et al. 1988, Thompson et al. 1988). The number of carboxylate 
and sulfate groups in the disaccharide units determine the 
overall negative charge density of a specific type of 
proteoglycan. The average number of sulfate residues in each 
disaccharide repeating unit is 2. 5 in heparin and 1. 5 in 
chondroitin sulfate E. 
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These differences in charge are the basis for 
histochemical techniques which utilize metachromatic dye 
staining. These techniques were first used to identify mast 
cell subsets in rodents (Enerback 1966) . Metachromatic dyes 
are cation dyes such as toluidine 0, alcian blue and safranin 
o. When certain tissue elements are stained with one of the 
dyes, the color of the dye changes from blue to a purple or 
reddish violet color, i.e. the absorbance of the dye changes 
from a higher wavelength to a lower wavelength in the 
reaction. The change in color is called metachromasia. The 
tissue elements capable of inducing metachromasia are called 
chromotropes and are usually polyanions such as heparin and 
chondroitin. The dyes resulting in metachromasia are called 
metachromatic dyes. The chemical theory of metachromasia has 
been discussed (Schubert & Harnberman 1956) . Metachrornatic 
dyes contain chromophobic groups which exist in two tautomeric 
forms in a resonance system. Each tautomeric form has its own 
energy level for the 1f electrons and absorbs light of a 
characteristic wavelength. A reversible shift in the 
equilibrium between the two tautomeric forms of the dye 
results in a color change. It has been found that 
polymerization of metachrornatic dyes results in a shift of the 
equilibrium of the molecular species in the resonance system. 
Chromotropes with their negative charges close together can 
bind cationic metachrornatic dyes through salt bridges. The 
binding brings the dye molecules into close contact which 
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initiates polymerization. These shifts the peak absorption 
spectra to a shorter wavelength resulting in metachromasia. 
Alcian blue 8 GX is a metachromatic dye containing four 
isothiouronium groups (Scott 1972). Alcian blue differs from 
other proteoglycan stains in that it does not stain nucleic 
acids and has a high solubility even in the presence of high 
salt concentrations. At pH 2.5-2.7, alcian blue stains both 
sulfated and non-sulfated proteoglycans, giving a blue color. 
At pH 1, only the sulfated glycosaminoglycans are stained 
(Pearse 1968). Safranin O is a metachromatic dye used to 
stain highly sulfated proteoglycans such as heparin. The less 
sulfated condroitin sulfate does not bind safranin O well. 
Together with alcian blue, safanin has been used to identify 
rodent mast cell types based on their metachromatic staining 
properties (Enerback 1966). 
Utilizing those properties of the chromotropes and 
metachromatic dyes, Enerback and others demonstrated two types 
of mast cells in rodent (Enerback 1966, Miller & Walshaw 
1972). In these experiments, mast cells in different tissues 
were fixed, and stained first with alcian blue and then with 
safranin stain. It was found that mast cells in the 
intestinal lamina propria were stained blue with the alcian 
blue but remained blue upon subsequent staining with safranin. 
On the other hand, mast cells in the skin and peritoneal 
cavity turned red after double staining indicating staining by 
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safranin. These observations resulted in the classification 
of rodent mast cells into two subtypes, the mucosa! type mast 
cells (MMC) from the intestinal mucosa! and the connective 
tissue type mast cell (CTMC) from skin and peritoneal lavage. 
subsequent experiments found that these two types of mast 
cells appeared to exhibit differences in many aspects 
including the response to cytokines and various 
pharmacological agents as well as mediator content as 
discussed above. The terms MMC and CTMC ref er to the 
phenotype rather than the tissue location of mast cells 
because each of them may be found both in mucosa! and 
connective tissue sites. 
Histochemical techniques relying on the metachromatic 
dyes has limitations which can not be over emphasized. As 
observed earlier (Combs et al. 1965), inunature CTMC cells 
exhibit MMC staining properties presumably due to their lack 
of heparin. In contrast to rodent mast cells which have 
distinct proteoglycan content in the majority of the two mast 
cell subtypes, human mast cells isolated from both skin and 
lung have heparin proteoglycans as measured (Metcalfe gt al. 
1979, Metcalfe et al. 1980, Eliakim et al. 1986, Stevens et 
al. 1988, Thompson gt al. 1988). The presence of heparin in 
the two potentially different types of mast cells abolishes 
the discriminating basis for the metachromatic staining 
techniques in human. 
Immunohistochemistry. Immunohistochemical techniques 
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have become the tools of choice in the recent years to 
identify subtypes of mast cells in the human and rodent (Irani 
~ al . 19 8 6, Gibson gt_ al. 19 8 7) . The techniques uses 
tryptase and chymase of mast cell granules as the pref erred 
markers. Trypsin-like activity was originally demonstrated in 
human mast cells by histochemical techniques (Glenner & Cohen 
1960, Chiu & Lagunoff 1972). Tryptase has been found to be 
the principal enzyme accounting for the trypsin-like activity 
in human mast cells (Schwartz et al. 1981a). The amount of 
tryptase found in human mast cells (10-35 pg/cell) accounts 
for 20-50% of the total protein in the cells (Schwartz et al. 
1981b) . In contrast to mast cells, only a negligible amount 
of the enzyme (<0. 04 pg/cell) was measured in human basophils. 
No detectable amount of tryptase has been measured in other 
cell types in normal skin, lung bowel, and eosinophils, 
neutrophils, monocytes, or lymphocytes from peripheral blood. 
Sequential staining with alcian blue followed by either 
immunoperoxidase or immunofluorescence using a monoclonal 
murine anti-tryptase antibody showed a one-to-one correlation 
between anti-tryptase-positive cells and alcian blue-positive 
cells, which means that all cells with tryptase are mast cells 
as demonstrated by the metachromatic property (Schwartz 1985). 
Results from electron microscopy showed tryptase-positive 
stain in immature mast cells which have newly formed granules 
(Craig et al. 1989). Evidence also indicated that tryptase 
appears in cultured human fetal liver mast cell granules prior 
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to the acquisition of their metachromatic properties (Irani & 
Schwartz 1990} . Thus, tryptase has been chosen as a highly 
selective and specific marker for human mast cells. In 
dispersed human foreskin mast cells, a substantially lower 
amount of chymase (94.5 pg/cell} was found in comparison to 
tryptase in the same cell type ( Irani et al. 1986}. Based on 
the specific location of the enzymes, tryptase and chymase 
have been convincingly applied to classification of mast cell 
subtypes in humans. 
The presence of chymase activity in rat mast cells was 
also demonstrated some time ago by histochemical techniques 
(Benditt & Arase 1959} . Two types of chymase have been 
located in rat mast cell granules (Miller et al. 1990} . 
Chymase I is found exclusively in CTMC-type and chymase II in 
MMC. The amount of chymase I (24-30 pg/cell} accounts for 
about 25% of the total proteins in the CTMC type cell 
(Schwartz et al. 1981). An equivalent amount of chymase II 
(26 pg/cell} was found in cultured MMC (Haig et al. 1982). 
Using human lung, skin, and small intestine fixed in 
Carney's solution, Irani's group (Irani et al. 1986} 
demonstrated two distinct human mast cell types using a 
polyclonal rabbit anti-chymase and a monoclonal murine anti-
tryptase antibody. First, they performed single staining in 
adjacent tissues. The results showed that all mast cells 
stained tryptase-positive. However, only skin, intestinal 
submucosal, and peribronchial mast cells, but not intestinal 
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mucosal or lung alveolar mast cells, stained chymase positive. 
These results indicated the presence of different mast cells 
based on their protease content. Second, in order to confirm 
that those cells with chymase also contain tryptase, 
simultaneous double labelling experiments were performed by 
incubating the two antibodies simultaneously with the same 
sections. Then chymase-positive cells were stained blue using 
an alkaline phosphatase reaction followed by staining of 
tryptase-positive cells using peroxidase. The results showed 
that all cells that first stained blue turned dark brown 
following the subsequent stain suggesting that chymase truly 
co-resides with tryptase in the same cell (Irani et al. 1989}. 
Finally, in order to demonstrate the presence of two distinct 
mast cell types in the same tissue section, sequential double 
labeling experiments were performed. Sections were first 
incubated with the anti-chymase antibody, and developed to 
give clusters of brown color which happen to interfere with 
the subsequent stain. The sections were subsequently 
incubated with the anti-tryptase antibody followed by 
development of the alkaline phosphatase blue stain. Cells 
containing chymase remained brown while those with tryptase 
but without chymase were stained blue. The results confirmed 
the existence of the two types of mast cells. Human mast 
cells were therefore divided into two subtypes, the MCT type 
which contains tryptase only, and the M~c type which contains 
both tryptase and chymase. Using a newly developed monoclonal 
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murine anti-chymase antibody and the murine anti-tryptase 
antibody, Irani ~ gl. confirmed their previous findings in a 
varieties of human tissues (Irani ~ al. 1989, 1990). 
Electron microscopic evidence also provided strong 
support for the classification of the two human mast cell 
types. Ultrastructural studies using double immunogold 
staining procedures showed that all granules in MCrc cells 
contained both tryptase and chymase and that the MCr cell 
granules had only tryptase (Craig et al. 1988). Subsequent 
studies based on enzyme activity assay, mediator contents, and 
the response of the MCT and MCTc types to cytokines showed 
differences between the two types of human mast cells. 
Synthetic substrates are also available for detection of 
tryptase and chymase activities in tissue sections (Osman et 
al. 1989). The experiments likewise showed tryptase activity 
in all mast cells in human intestine while chymase activity 
was detected only in the submucosal mast cells. Mast cells 
with chymase activity also demonstrated tryptase activity. 
Thus, the intestinal mucosa! mast cells are predominantly MCT 
type while the submucosal mast cells are MCTc type. These 
observations confirm the distinction between the two mast cell 
types based on immunohistochemical results. 
The two different mast cell types have been related to 
different diseases. In patients with congenital disorders 
affecting T cell functions or with AIDS and combined 
immunodeficiency, a significant decrease in the MCT type was 
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detected from the analysis of gastrointestinal tissues of the 
patients while the MCn; type was virtually not affected (Irani 
~ gl. 1987a). In synovium of rheumatoid arthritis subjects, 
where heavy lymphocyte infiltration occurs, a mixture of MCr 
and MCrc types were found while usually only MCrc type is 
present in the normal synovium (Irani et al. 1987b). These 
observation indicate that activity of MCr cells may be 
lymphocyte factor dependent. The significance of the 
innnunohistochemical techniques is also demonstrated by the 
ability to distinguish the two subtypes in immature human mast 
cells. Coupled with electron microscopy, Craig's group 
observed that the amount of MCr and MCTc found in immature mast 
cells in various tissues are parallel to those found in the 
counter part of the mature mast cells {Craig et al. 1989). 
In rat, immunohistochemical techniques have targeted two 
different forms of rat chymases found in rat mast cells, 
chymase I and chymase II {Gibson et al. 1987, Huntley et al. 
1990). In the experiments, polyclonal monospecific rabbit 
anti-chymase I and monoclonal mouse anti-chymase II were used. 
Adjacent sections of tissues from various sources were stained 
individually with anti-chymase I, anti-chymase II, and 
metachromatic dye such as toluidine blue or alcian blue and 
safranin 0. Populations of stained cells were counted and 
compared to the adjacent sections. A correlation was then 
drawn between the sections. The results provided high 
correlation of the chymase I-positive cells with the CTMC type 
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defined by the metachromatic properties and the chymase II-
positive cells with MMC. Although some overlap of chymase r-
and chymase II-positive cells were observed, the population of 
the cells is very small. A minor population of the chymase !-
positive cells were shown to be MMC type in both nonmucosal 
and mucosal tissues. The results suggest that granule 
protease phenotyping can be an alternative techniques in 
identifying mast cell subsets in rodent system. 
Although tryptase has been purified from rat tissues, no 
information is available regarding its distribution among rat 
mast cells. 
5. Purposes Of The Project 
As reviewed above, mast cells play an important role in 
health and diseases. However, investigation of the specific 
mechanisms involved in mast cell functions has been 
complicated by the existence of mast cell heterogeneity. Rat 
is one of the major sources of our knowledge about mast cell 
functions. Thus it is very important to identify 
heterogeneity of rat mast cells for interpretation of data and 
comparison to the human system. Successful identification of 
human mast cell types suggested the possibility that rat mast 
cell types could be distinguished in a similar way. 
Demonstration of chymase I-positive and chymase II-positive 
rat mast cell types provided a basic reference for detecting 
rat mast cell types based on the contents of their neutral 
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proteases. 
A tryptase has been purified and characterized from rat 
skin in our lab. It was our goal to raise a polyclonal anti-
rat tryptase antibody and localize the enzyme in rat skin, 
lung, peritoneal lavage cells, and small intestinal mucosa. 
To do this, antibody specificity would first be evaluated by 
ELISA and Western Blot using the purified tryptase as antigen. 
rmrnunohistochemistry techniques would be used to identify mast 
cells containing tryptase and/or chymase. Mast cell 
distribution in the tissues would be evaluated with the 
metachromatic dyes, alcian blue and safranin O. Single 
staining with alcian blue, anti-tryptase, and anti-chymase I 
antibodies would provide data for distribution of total mast 
cells, tryptase-containing mast cells, and chymase I-
containing mast cells, respectively, in the tissues. Double 
staining with metachromatic dye followed by anti-tryptase or 
anti-chymase I would confirm the existence of the proteases in 
the metachromatic mast cells. At the same time, it would 
allow correlation between the CTMC and MMC types with 
tryptase-positive or chymase I-positive cells. In order to 
verify if tryptase and chymase I co-reside in the same cell, 
simultaneous double labeling would be performed by labeling 
the tissue sections with both anti-tryptase and anti-chymase 
I antibodies simultaneously followed by developing the 
corresponding colors one after the other. As a confirmation 
of the existence of two distinct mast cell types, tissue 
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sections would be labeled with the anti-tryptase antibody 
first followed by color development. Then the sections will 
be labeled a second time with anti-chymase I antibody to 
confirm the distinct types of mast cells based on the presence 
of the enzymes. 
A. Materials 
CHAPTER VIII 
MATERIALS AND METHODS 
Alcian blue SGX, safranin 0, diaminobenzidine, 3-amino-9-
ethylcarbazole, ~02 (30%), and peroxidase-conjugated rabbit 
anti-goat IgG were obtained from Sigma Chemical Co., St. 
Louis, MO, Molecular weight standards were from Pharmacia, 
Piscataway, NJ and peroxidase-conjugated swine anti-goat IgG 
from Boehringer Mannheim, Indianapolis, IN. Rabbit IgG anti-
chymase I had been made specific for chymase I by adsorption 
with chymase II and affinity purification with chymase I 
(Gibson & Miller 1986) . Tryptase used for immunization and 
various immunochemical procedures was purified to homogeneity 
from rat skin as described (Braganza & Simmons 1991). Lung, 
skin and peritoneal cells were from normal Sprague Dawley 
animals; bowel was taken 14 days after infection of Lewis rats 
with Nippostrongylus brasiliensis (3000 organisms/animal) as 
described previously (Befus & Bienenstock 1979) to amplify the 
number of mucosal mast cells in the intestine. Samples of 
lung, skin and bowel fixed in Carnoy's fluid for 24 hours and 
then transferred to absolute ethanol. Tissues were embedded 
in paraffin. Sections of lung and bowel tissues were 4 µ, 
while those for skin was 5 µ. Rat peritoneal cells were 
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collected from the lavage with PBS solutions {Appendex E) and 
subjected to cytocentrifugation. Each slide contained 2 x 104 
viable cells. 
B. Methods 
1. Western Blot 
Protein extracts were prepared from rat skin {10 g), 
lung, {2.3 g), bowel {2.5 g), and peritoneal cavity cells {4 
x 107 cells) . In the case of skin, cutaneous muscle and fat 
layer were removed and the fur was clipped away as close as 
possible to the dermis. The lung and bowel tissues were 
rinsed well with tap water followed by MQ water. All tissues 
were cut into small pieces before extraction. The skin tissue 
was homogenized at a 1:9 {w/v) ratio in the homogenization 
buff er {Appendix D) using a Polytron homogenizer at full speed 
for three 15 second on-off intervals. The lung and bowel 
tissues were homogenized at 1: 5 {w/v) ratio in the same 
buffer. Peritoneal lavage cells were ultrasonicated for three 
20 second pulses on ice. The homogenate was centrifuged at 
18,000 xg for 40 minutes at 4 °C. The supernatants from the 
tissue extracts were stored at -20 °C after assaying for 
tryptase activity. The skin and peritoneal lavage cell 
extracts were subjected to TCA precipitation. Extract {500 
µl) was mixed with an equal volume of 20% TCA {Appendix D) and 
kept on ice for 5 minutes. The proteins were precipitated by 
centrifugation at 4 °C for 10 minutes. The pellet was rinsed 
with 500 µl of acetone twice. 
was resuspended in 5 µl of 
(Appendix B) . 
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After air drying, the pellet 
the SOS-PAGE sample buffer 
The crude extracts were assayed for tryptase and chymase 
activities. The tryptase assay reaction contained 850 µl of 
the tryptase assay buffer (Appendix A), 50 µl of the crude 
extract, and 100 µl of 10 mM BAEE (Appendix A) . The reaction 
was monitored at 253 nm for 5 minutes. The amount of tryptase 
was estimated using a specific activity of 160 units/mg 
protein in the formula presented in Part I. The chymase 
reaction contained 500 µl of the chymase assay buffer 
(Appendix D), 33 µl of the crude extract, and 467 µl of the 1 
mM BTEE (Appendix D). The reaction was monitored at 256 nm 
for 5 minutes. 
Protein concentrations of the crude extracts were 
determined using protein assay reagent A and B from Pierce 
Chemical Company, Rockford, Illinois. The assay reagent 
consisted of 1:50 ratio of reagent A:B. Each microtiter well 
contained 10 µl of the sample and 200 µl of the reagents. 
Five BSA concentrations of 25, 100, 200, 300, and 500 µg/ml 
were used as standards. Color development was allowed to 
continue at 37 °C for 30 minutes. Protein concentrations were 
measured at 562 nm on a Micoplate Reader. The standard 
protein concentrations were plotted against the absorbance 
values. Sample protein concentrations were determined using 
the regression equation derived from the standard curve. 
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Western blot was performed as described (Towbin ~ gl. 
1979, Bollag & Edelstein 1991). The protein samples were 
separated in SDS homogeneous 12.S PhastGel using PhastSystem. 
Each lane was loaded with 20 µg of the protein extracts or 
purposely over-loaded with 30 µg of the extracts to evaluate 
any nonspecific binding activity of the antibody. Two 
identical gels were run simultaneously under the same 
condition. The samples were separated using the following 
program: 
Separation Program 2 
Sample Appl. Down At 
Sample Appl. Up At 
Sep. 2.1 250 v 
Sep. 2.2 50 v 
10 mA 
0.1 mA 
3 w 
0.5 w 
15 °C 
15 ~ 
2.1 
2.1 
1 vh 
10 vh 
60 vh 
0 vh 
After the separation, one gel was subject to coomassie blue 
stain using the following development program: 
Development Program 2 
110 
steps In-port Out-prot Time Temp. 
{min) {°C) 
2.01 4 0 10 50 
2.02 2 0 5 50 
2.03 2 0 8 50 
2.04 2 0 10 50 
2.05 9 0 5 50 
where in-port 4 connects to the stain solution {Appendix D); 
in-port 2 connects to the destain solution {Appendix D); in-
port 9 connects to the preservative solution {Appendix D) ; and 
out-port O connects to the waste collection bottle. 
The companion gel was used for blotting. A nitrocellulose 
membrane {0.45 µm), six pieces of blotting paper, and the gel 
were soaked in a PhastTransfer buffer {Appendix D) for 5 
minutes. Then, the gel was clamped to a mounting block and 
separated from the plastic gel backing. The nitrocellulose 
membrane was carefully laid on the gel in order to remove the 
gel from the plastic backing. The transfer sandwich consisted 
of 3 pieces of the wetted blotting paper at the bottom, the 
nitrocellulose membrane with the gel attached to the upper 
side, and, on the top of the sandwich, another 3 pieces of the 
blotting paper soaked in the transfer buffer. A semi-dry 
electrophoretic transfer was performed on a PhastTansfer 
system using the following program: 
separation Program 3 
sample Appl. Down At 
sample Appl. Up At 
Sep. 3.1 20 v 25 mA 1 w 15 °C 
3.0 0 vh 
3.0 0 vh 
5 vh 
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Blotting one gel requires 15-20 minutes. A longer time of 30-
40 minutes may be necessary when blotting two gels 
simultaneously. After transfer, the nitrocellulose membrane 
was pealed off the gel carefully, rinsed in the transfer 
buffer and dried briefly between 2 pieces of the 3 mm paper. 
The nitrocellulose membrane was blocked in 12 ml of the 
blocking buffer {Appendix D} in a Seal-A-Meal plastic bag for 
1 hour with gentle rocking. After blocking, the membrane was 
rinsed briefly with TBS {Appendix D} three times and incubated 
with the goat anti-rat tryptase antibody overnight at 4 °C 
with gentle rocking. The antibody concentration was 5 µg/ml 
in O. 5% BSA/TBS solution {Appendix D} . After washing with TBS 
for 10 minutes three times at room temperature, the membrane 
was incubated with 12 ml of the second antibody solution 
{Appendix D} for 2 hours at room temperature and washed again 
with TBS for 10 minutes for three times. When the color was 
fully developed in the AEC/~02 solution {Appendix D}, the 
reaction was terminated by rinsing the membrane with tap water 
briefly followed by rocking in MQ water for 30 minutes. 
Finally, the membrane was dried on 3 mm paper and 
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photographed. 
2. Tissue Section Preparation 
Skin, bowel, and lung tissues from Sprague Dawley rats 
were fixed in Carney' solution {Appendix B) and embedded in 
paraffin wax by Dr. G. Newlands and Dr. S.S. Craig in the 
Medical College of Virginia. The bowel tissue was obtained 
from N. Brasiliensis-infected animals. Sections of lung and 
bowel {4 µm) and skin (5 µm) were prepared. 
Rat peritoneal lavage cells were obtained by a 
modification of the method of Saeki (Saeki 1964). Animals 
were decapitated with an animal guillotine, and exsanguinated. 
Fifteen milliliters of PBS/Heparin buffer (Appendix B) were 
injected into the peritoneal cavity. The abdominal wall was 
massaged gently and the body was turned around a few times. 
The fluid was collected by cutting along the midventral line 
of the abdomin and flipping the opening downward into a 
funnel. Peritoneal lavage cells from two rats (30 ml) were 
spun down at 1,000 rpm in a swinging rotor for 10 minutes at 
room temperature and resuspended in 5 ml of PBS/DNase buffer 
(Appendix B) . Viable cell concentration was determined in the 
following manner. Cells were first stained with Trypan at a 
1:1 ratio of cell/trypan (v/v) in which intact cells remained 
colorless while dead cells turned blue. The number of viable 
cells was counted under a microscope using a 25 grid counting 
chamber. The concentration of the peritoneal lavage cells was 
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calculated using the following formula: N x D x 104 = C 
where N is the number of the viable cells counted in the 25 
grid area; D is the total dilution factor of the cell 
solution; and C is the final concentration in number of viable 
cells/ml. About 2 x 104 peritoneal lavage cells were adhered 
to each slide by centrifugation at 600 rpm for 6 minutes at 
room temperature using a cytospin centrifuge. 
Before staining, the cytospin slide with peritoneal 
lavage cells was fixed in Carney's solution at room 
temperature for 15 minutes and washed in HzO for 5 minutes. 
The paraffin embedded sections were dewaxed and rehydrated 
before staining. The sections were first dewaxed in three 
changes of xylene, 5 minutes each. Then, they were submerged 
through two changes of 100% ethanol for 5 minutes and 3 
minutes respectively. Endogenous peroxidase was inactivated 
by incubation of the sections with a Hz02/methanol solution 
(Appendix E) for 30 minutes. Finally, the sections were 
rehydrated through 95%, 80%, 70%, and 50% ethanol for 5 
minutes each, and then in MQ water for 3 minutes. 
3. Histochemical Stain 
Alcian blue was used to identify mast cells in the 
tissues. A rehydrated section was stained in 0.1 ml of 0.5% 
of alcian blue solution (Appendix F) for 30 minutes at room 
temperature. The alcian blue was rinsed off the section 
gently with MQ water. A drop of 90% glycerol from a needle 
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was laid on each section and then covered with a piece of the 
cover glass. If a second stain were to follow, the cover 
glass was placed lightly on top of the section. For long term 
storage, excess glycerol was pressed out of the cover glass 
and wiped away with a piece of Kimwipe. 
Safranin O was used to stain the connective tissue type 
mast cells. A rehydrated tissue section was stained with 0.1 
ml of a 0.1% safranin solution (Appendix F) for 5 minutes at 
room temperature. After rinsing off the safranin with MQ 
water, the section was mounted either to glycerol when a 
second stain was required or to permount for long term 
storage. 
Alcian blue/safranin double stain was used to evaluate 
the distribution of the CTMC and MMC types of mast cells in 
the tissues. A tissue section was first stained with alcian 
blue. After rinsing off the alcian blue a few times with MQ 
water, the section was mounted in 90% glycerol and lightly 
covered with a piece of the cover glass. Different fields in 
the section were photographed under a microscope. The slide 
was soaked in water at 37 °C for 10-30 minutes to remove the 
cover glass. 
was dried 
Following a second safranin stain, the section 
thoroughly in air and mounted to permount. 
Photomicroscopy was performed on the same fields taken after 
the alcian blue stain. 
4. Inununohistochemical Stain 
.s_ingle Stain 
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A goat anti-rat tryptase antibody generated in 
or. L.B. Schwartz' lab was used to localize tryptase in lung, 
skin, bowel, and peritoneal lavage cells. A series of 
dilutions from a stock of 29 mg/ml was used to titer the goat 
anti-rat tryptase antibody. The stock was diluted to 29, 23, 
20, 16, 15, 10, 5, 1, and 0.5 µg/ml in PBS/BSA solution 
(Appendix F) . The rehydrated tissue sections were blocked for 
non-specific binding of the second antibody with O .1 ml of the 
normal serum from the same species as the second antibody for 
2-3 hours at room temperature. Then the sections were washed 
in MQ water for 2 minutes and incubated with the anti-tryptase 
IgG at the above dilution overnight at 4 °C in a moisture 
chamber. The next day, the sections were rinsed gently with 
MQ water and washed through 3 changes of TTBS (Appendix F) for 
5 minutes each and then with MQ water for 2 minutes. A 1:50 
dilution of the peroxidase-conjugated swine anti-goat IgG was 
incubated with the sections for 1 hour at room temperature. 
Washing the sections through 3 changes of TTBS for 5 minutes 
each and one change of water was sufficient to rinse the 
unbound IgG away before the color reaction. Reddish brown 
color for the stained cells appeared after incubation of a 
section with 0.1 ml of the AEC/Hz02 solution (Appendix F) for 
7 minutes at room temperature. 
with water and mounted in 
The sections were then rinsed 
90% glycerol. The optimal 
concentration was determined from the titration experiments 
and used for all of the other experiments. In the anti-rat 
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tryptase stain experiments, a goat anti-rat chymase I antibody 
was used as a positive control for all the tissues tested. 
preimmune goat IgG which was collected before the goat was 
primed with rat tryptase provided a negative control for the 
anti-tryptase experiments. Both the positive and negative 
experiments used the same procedure described above except 
that the anti-tryptase IgG was replaced with either the anti-
chymase in the positive or the preimmune goat IgG in the 
negative controls. 
A polyclonal rabbit anti-rat chymase I monospecific 
antibody was used to locate rat chymase I in the tissues. A 
stock solution of 80 µg/ml was diluted into 1.6, 3.2, and 10 
µg/ml and titered for its optimal concentration on rat lung, 
skin, bowel, and peritoneal lavage cell preparations. A 1:50 
dilution of peroxidase-conjugated goat anti-rabbit IgG was 
used as a second antibody. 
Double Staining. Alcian blue/tryptase sequential stain 
combined the single staining procedure for the two stains 
together. The rehydrated sections were stained with alcian 
blue first. After performing photomicroscopy, the section 
were stained for rat tryptase. Cells which contained tryptase 
changed their color from blue after the alcian blue stain to 
brown following the tryptase stain using AEC. Finally, the 
sections were mounted on 90% glycerol and the same fields were 
photographed. 
Safranin/tryptase sequential stain must be performed by 
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staining the tissue with safranin first and then staining for 
tryptase. The red color from the safranin stain disappeared 
during the subsequent tryptase stain. Likewise, the tryptase 
staining procedure somehow prevented the tissue from getting 
stained by safranin. Unlike in the alcian blue/tryptase 
stain, safranin/tryptase stain used DAB/~02 (Appendix F) as 
substrate for the color development. Cells stained red by 
saf ranin would turn dark brown after the DAB/~02 reaction if 
the cells contained tryptase. The disappearance of the red 
safranin color in fact provided easy identification of the 
positive cells in the second stain. 
Alcian blue/chymase I sequential stain basically followed 
the same procedure as the alcian blue/tryptase stain except 
that after alcian blue stain, the sections were blocked with 
normal goat serum for 3 hours. The primary antibody used was 
the rabbit anti-rat chymase I IgG. The second antibody was 
a 1:50 dilution of peroxidase-conjugated goat anti-rabbit IgG. 
AEC/~02 was used as the substrate for the color reaction. 
Simultaneous Double Labeling With Anti-Tcyptase And Anti-
Chymase I Antibodies. The prepared sections were blocked 
with normal swine serum at room temperature for 3 hours. 
After rinsing with MQ water, the sections were incubated with 
5 µg/ml of the goat anti-tryptase antibody and 3.2 µg/ml of 
the rabbit anti-chymase I antibody simultaneously at 4 °C 
overnight. The antibodies were washed away through 4 changes 
of TTBS, 5 minutes each, and one change of MQ water. A 1:50 
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dilution of alkaline phosphatase-conjugated swine anti-goat 
IgG was incubated for 1 hour with the sections in the presence 
of o. lt of normal rabbit serum. The normal rabbit serum 
prevented swine anti-goat IgG from binding nonspecifically to 
the rabbit anti-rat chymase I. The sections were washed 
through 3 changes of TTBS and one change of MQ water again, 
and then developed in the Naphthol/Fast Blue solution in the 
dark until the blue stained cells were clearly seen under the 
light microscopy. Tryptase-positive cells which stained blue 
were counted and photographed. To identify chyma.se I-positive 
cells, the sections were incubated with peroxidase-conjugated 
goat anti-rabbit IgG at room temperature for 1 hour and then 
developed in AEC/~02 solution. Blue cells which contained 
tryptase turned dark brown indicating that chyma.se I resides 
in the same cells as does tryptase. Photomicroscopy of the 
same fields was repeated. Four controls were run in parallel 
to the samples. Instead of using both antibodies, the first 
one contained only goat anti-rat tryptase antibody without the 
rabbit anti-chyma.se I antibody. This control would verify 
whether the second peroxidase-conjugated goat anti-rabbit IgG 
might cross-react with the goat anti-tryptase antibody. The 
second control was the opposite to the first. It contained 
only the rabbit anti-chymase I antibody without the goat anti-
tryptase antibody. This control would reveal any nonspecific 
binding of the alkaline phosphatase-conjugated swine anti-goat 
IgG to the rabbit anti-chymase I antibody in the presence of 
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o .1% normal rabbit serum. The third control contained neither 
one of the two primary antibodies but MPC-11, a murine myeloma 
IgG, kappa, which has no known antigenic specificity. Any 
nonspecific binding of either one of the secondary antibodies 
to IgG would be detected under this control. In the fourth 
control, the two primary antibodies were replaced by PBS/BSA 
to see if the secondary antibodies may bind nonspecif ically to 
the tissues. 
sequential Double Labeling With The Anti-Tryptase and Anti-
Chymase I Antibodies. Tissue sections were blocked with 
normal swine serum for 3 hours and rinsed with MQ water 
briefly. The first overnight reaction contained 5 µg/ml of 
goat anti-tryptase antibody in the PBS/BSA solution incubated 
with the sections at 4 °C. After washing with three changes 
of TTBS, 5 minutes each, and one change of MQ water the next 
day, the sections were incubated with peroxidase-conjugated 
swine anti-goat IgG at room temperature for 1 hour. The color 
reaction was developed in AEC/H202 solution as described above. 
Then, the slides were mounted lightly in 90% glycerol and 
photographed. The cover glasses were removed in MQ water at 
37 °C. In the second overnight reaction, the tissues were 
incubated with 3.2 µg/ml of the rabbit anti-chymase I 
antibody. The next day, the antibody was washed away with 
three changes of TTBS and one change of MQ water again. After 
an one-hour incubation with alkaline phosphatase-conjugated 
goat anti-rabbit IgG, the sections were washed with TTBS and 
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MQ water and then developed in the Naphthol/Fast Blue solution 
for 15 minutes in the dark. Photomicroscopy of the same 
fields were then performed. Tryptase-positive cells were 
stained reddish brown by AEC. The color deposit somehow 
blocked the subsequent stain. As a result, any cell staining 
blue after the second stain indicated the presence of chymase 
I alone in the cell. 
5. Photomicroscopy And Calculations 
Photomicroscopy was performed with a Zeiss Ultraphot 
microscope {Carl Zeiss, Inc., Thornwood, N.Y.) using Kodak 
Ektachrome 64T films. For reflected light photomicroscopy, a 
didydium filter and a TIFFEN 49 nun, 82 °C filter were used. 
For phase contrast, only the didydium filter was used. The 
pictures were taken at either 160 x magnification using a 40 
x oil lens or 250 x using a 63 x oil lens. 
Assessment of tissue surface area was obtained with a 
Zeiss Videoplan apparatus. In lung sections, only the 
peribronchial areas were measured. In the bowel sections, 
more than a dozen of the randomly selected areas were measured 
and positive cells counted. In skin, the area of a whole 
section was usually included. Mast cell concentrations were 
determined as described previously (Irani et §l.. 90): 
Mast Cells/nun3 = [Mast Cells/nun2] x [103 / { 10 µm + 4 µm)] 
where 10 µm was used as an estimate of the average mast cell 
diameter and 4 µm was the tissue thickness for lung and bowel; 
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s µm was used for the thickness of skin. 
CHAPTER IX 
RESULTS 
1. Specificity Of Goat Anti-Rat Tryptase Antibody 
To examine the specificity of the anti-tryptase IgG, 
western blots were perf armed as shown in Figure 12. Lanes 1- 4 
show the results of the Western blot; lanes 5-8 show the 
Coomassie blue stain of an identically prepared gel run in 
parallel. Lanes 1 and 8 each contained 20 µg of the initial 
extract from rat skin and 100 ng of purified tryptase; 
respective lanes 2 and 7 were identical except for lack of 
purified tryptase. Lanes 3 and 6 contained 20 µg of the crude 
protein extract from rat peritoneal lavage cells. Lanes 4 and 
5 contained 20 µg of the crude extract from rat lung. Amounts 
of tryptase in these extracts was estimated based on the 
specific activity of the enzyme purified from skin and the 
enzymatic activity in each extract using benozyl-arginine 
ethyl ester. In each case there was less than 1 ng of 
tryptase applied to the gel. The sensitivity of the Western 
blot technique for purified tryptase was approximately SO ng; 
approximately 500 ng tryptase were needed for detection by 
Coomassie blue. Accordingly, tryptase was detected 
inununologically in lane 1, but not in lanes 2, 3, and 4. The 
results do show a lack of binding to 
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Figure 12. Specificity Of Goat IgG Anti-Rat Tryptase. A 
Western blot {lanes 1-4) and Coomassie blue-stained 
polyacrylamide gel {lane 5-8) containing extracts of skin 
(lanes 1, 2, 7 and 8, 20 µg protein/lane), peritoneal cells 
{lanes 3 and 6, 20 µg protein/lane) and lung {lane 4 and 5, 20 
µg protein/lane) . Purified rat tryptase was included in lanes 
1 and 8 {100 ng/lane). Molecular weight standards used 
included phosphorylase b {94,000), albumin {67,000), ovalbumin 
(43,000), carbonic anhydrase {30,000), ~1-trypsin inhibitor 
(20,100), and ~-lactalbumin {14,400) {Pharmacia). 
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the numerous other proteins present in each tissue extract, 
indicating a high degree of specificity for tryptase. 
2. Distribution Of Mast Cells And Tryptase Positive Cells 
The distributions of connective tissue (red) and mucosal 
(blue) types of mast cells by staining with alcian blue and 
safranin, and tryptase-positive cells by immunohistochemistry 
were determined in comparable sections of skin, bowel, and 
lung and in cytospin preparations of peritoneal cells. In 
lung, mast cells were detected primarily in peribronchial 
tissue, 53% being of the connective tissue type (Table 3) . In 
contrast to the situation in human lung, few mast cells were 
detected in the rat lung alveolar wall. In skin, most of the 
mast cells were located in the dermis and in the layer under 
the adipose tissue, and in each case were 81% connective 
tissue type. In the bowel mucosa from fi. brasiliensis-
infected animals, mucosal (safranin-negative) mast cells were 
abundant, accounting for >99% of the mast cells. Mast cells 
obtained by peritoneal lavage accounted for 5-10% of the 
cells, and over 95% were of the connective tissue type 
(safranin-positive) . 
Tryptase-containing cells also were assessed in lung, 
skin bowel and peritoneal cells using goat IgG anti-tryptase 
antibody. No staining was observed using preimmune goat IgG 
as a negative control. Tryptase-containing cells were most 
abundant in lung, where they were distributed in a 
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peribronchial location. Among peritoneal cells they accounted 
for only 20% of the cells. In skin, tryptase-positive cells 
were detected in the dermis and below the hypodermis, but at 
concentrations that appeared to be less than for mast cells 
detected histochemically. In bowel mucosa there were 
essentially no tryptase-positive cells. 
3. Rat Tryptase Is Localized In Mast Cells 
To determine whether tryptase-containing cells were mast 
cells and only mast cells, sequential staining with Alcian 
blue and anti-tryptase antibody was performed. For example, 
in a section of rat lung, among 4 Alcian blue-stained mast 
cells (Figure 13A) , two stained positive for tryptase (Figure 
13B) . In these double labelling experiments, the 
concentration of mast cells in peribronchial tissue was about 
15 x 103 cells/mm3 , 63 ± 8% contained tryptase (Table 3). In 
rat skin, two Alcian blue-positive mast cells are shown in 
Figure 13C, one of which stains positive for tryptase (Figure 
130). In general, tryptase-positive mast cells stained less 
intensely in skin than in lung. Tryptase-positive mast cells 
accounted for only 7 ± 4% of the 882 ± 136 mast cells/mm3 in 
the dermis (Table 3). A cluster of 7 mast cells obtained from 
the 
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Figure 13. Sequential Staining With Alcian Blue And Anti-
Tryptase Antibody. Tissue sections from lung (A, B) , skin (C, 
D), a cytospin of peritoneal cells (E, F), and bowel (G, H) 
were stained first with alcian blue (A, C, E, G) and then with 
goat IgG anti-tryptase/peroxidase (brown) (B, D, F, H). 
Identical fields for each cell source are shown. 
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H 
Cell Source MC/mm3 lSaf ranin"MC Tryptase+ x 100 · Tr.Yfil.flse+ x 100 
Peribronchus 
Dermis 
Bowel Mucosa 
Peritoneal 
Cells 
± SD 
(n) 
14,867 
± 3966 
( 6) 
882 
± 136 
( 6) 
32,264 
± 22,219 
(4) 
NA 
%Safranin+Mc 
± SD 
(n) 
47/53 ± 19 
(4) 
19/81 ± 8 
(6) 
100/0 ± 0 
(4) 
5/95 
( *) 
Alcian Blue+ Safranin+ 
± SD ± SD 
(n) (n) 
63 ± 8 94 ± 10 
(6) (4) 
7 ± 4 6 ± 2 
( 6) (4) 
ND ND 
(4) (4) 
19 ± 6 20 ± 8 
(12) (12) 
Table 3. Distribution Of Tryptase-Positive Mast Cells. The results of sequential 
alcian blue/tryptase and safranin/tryptase stains are summarized in the table. MC, mast 
cell; SD, standard deviation; n, number of tissue sections used; ND, not detectable; NA, 
not applicable; *, a total of 80 Safranin"/Alcian Blue+ mast cells among 1600 
Safranin+ /Alcian Blue+ mast cells. Areas of tissues examined were 2. 69 mm2 for 
peribronchus, 39.9 mm2 for dermis, and 17.0 mm2 for bowel mucosa. Sequential staining 
with alcian blue and safranin was used to determine %Safranin· and %Safranin+ mast cells. 
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peritoneal lavage is shown in Figure 13E, three of which 
contain tryptase (Figure 13F). The intensity of tryptase 
staining was comparable to mast cells in skin. Mast cells 
accounted for 8% of the total cells, 19% of which contained 
tryptase (Table 3). In rat bowel mucosa from IL.. brasiliensis-
infected animals, essentially none of the mast cells {32,264 
± 22,219 cells/mm3 ) (Table 3) that stained blue {Figure 13G), 
showed detectable tryptase (Figure 13H) . Bowel submucosa was 
not examined. The high standard deviation for the 
concentration of mast cells in the bowel reflect the uneven 
distribution of these mast cells in the cross sections of the 
bowel. Of 591 tryptase-positive cells examined in lung, skin, 
and peritoneal lavage cells, all stained with Alcian blue, 
implicating mast cells as the major source of this enzyme 
among the cells and tissues examined. 
Sequential staining with Alcian blue and anti-chymase I 
antibody showed that 60% of the Alcian blue cells in lung are 
chymase I-positive, over 85% of the Alcian blue cells are 
chymase I-positive in skin, 98% of the Alcian blue cells are 
chymase I-positive among peritoneal cells and none of the 
Alcian blue cells in bowel mucosa were chymase I-positive. 
4. Rat Tryptase Resides In The Safranin-Positive CTMC Cells 
To determine the distribution of tryptase-positive mast 
cells among safranin-positive and safranin-negative mast 
cells, sequential staining was performed, first with safranin 
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and then with anti-rat tryptase. The results revealed that 
all tryptase-positive cells were safranin-positive, but not 
all safranin-positive cells contained tryptase. For lung, 
Figure 14A shows 7 safranin-positive mast cells, six of which 
contained tryptase (Figure 14B} . In rat lung, over 90% of the 
safranin-positive cells are tryptase-positive (Table 3}. By 
contrast, in skin, 6 safranin-positive mast cells were shown 
in Figure 14C, only 1 of which was tryptase-positive (Figure 
14D} . Only about 6% of the safranin-positive cells in skin 
contained tryptase (Table 3). Bowel mucosa lacked safranin 
and anti-tryptase stainable cells. In peritoneal cells, 
Figure 14E shows numerous safranin-positive mast cells, most 
of which contained no detectable tryptase (Figure 14F} . 
Tryptase-positive cells account for only 19% of the rat 
peritoneal connective tissue mast cells (Table 3}. 
5. Distribution Of Tryptase And Chymase I In Rat Mast Cells 
Simultaneous double-labeling experiments were performed 
to determine whether tryptase-positive cells are also chymase 
I-positive. Figure 15A shows a section of lung which had 6 
blue tryptase-positive cells, all of which 
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Figure 14. Sequential Staining With SafraninAndAnti-Tryptase 
Antibody. Tissue sections from lung (A, B) and skin (C, D), 
and a cytospin of peritoneal cells (E, F) were stained first 
with safranin (red) (A, C, E) and then washed and stained with 
goat IgG anti-tryptase/peroxidase (brown) . Identical fields 
for each cell source are shown. The red safranin stain was 
removed by the washing procedure. All fields are shown under 
light microscopy except E, for which phase contrast was used 
to show stained mast cells along with unstained cells. This 
makes the red cells appear brown. 
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became dark brown (Figure lSB), indicating the co-localization 
of tryptase and chymase I in these cells. Of the lung mast 
cells which contained either tryptase, chymase I, or both, 77% 
contained both proteases, 4% contained only tryptase and 19% 
contained only chymase I (Table 4). Whether the small 
population of cells (4%) that stained for tryptase and not 
chymase I truly reflect chymase I-negative cells is not 
completely certain, because low levels of staining for chymase 
I may not produce sufficient brown staining to overcome the 
blue stain from tryptase. Figure lSC shows a section of skin 
which contained one blue tryptase-positive cell that became 
brown with the chymase I stain (Figure lSD) . Among the mast 
cells in skin which contained tryptase and chymase I, 9 6% 
contained only chymase I, 4% contained both proteases while no 
cells contained tryptase only (Table 4) . Figure lSE shows a 
section of peritoneal cells which had one blue tryptase-
positive cell that became brown with the chymase I stain 
(Figure lSF) as well as numerous chymase I-positive cells in 
which tryptase was not detected. Among the mast cells 
containing tryptase and chymase I in peritoneal lavage fluid, 
15% contained both protease, 85% contained chymase I alone, 
and none contained tryptase without chymase I (Table 4) . 
To better ascertain the distribution of two distinct 
mast cell types which contain either chymase I or tryptase 
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Figure 15. Simultaneous Double Labeling With Anti-Tryptase And 
Anti-Chymase I Antibodies. Sections of lung (A, B) and skin 
(C,D), and a cytospin of peritoneal cells (E, F) (phase 
contrast) were incubated simultaneously with goat IgG anti-
tryptase and rabbit IgG anti-chymase I antibodies. Sections 
were developed first with alkaline phosphatase-conjugated 
swine anti-goat IgG (blue) (A, C, E) and then with peroxidase-
conjugated goat anti-rabbit IgG (brown) (B, D, F). Blue 
tryptase-positive cells also containing chymase I turn brown; 
Those with tryptase but not chymase I remain blue; Those 
containing chymase I and not tryptase would appear brown, and 
never blue. 
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Cell Source 
Peribronchus 
Dermis 
Peritoneal 
Cells 
Cells* 
(n) 
45-60 
(5) 
159-299 
(7) 
110-300 
(12) 
Trmt~se+ x 100 Trypta~e+ x 100 Trmteli!!if x 1QQ 
Chymase r+ Chymase r Chymase r+ 
± SD ± SD ± SD 
77 ± 2 4 ± 2 19 ± 7 
4 ± 1 0 96 ± 1 
15 ± 2 0 85 ± 3 
Table 4. Simultaneous Labeling Of Tryptase And Chymase I. This table shows the results 
of the simultaneous double labeling of mast cells with anti-tryptase and anti-chymase I 
antibodies. SD, standard deviation; n, number of tissues used in the experiment; *, 
number of cells counted per section or slide. 
I-' 
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in a single section, sequential double-labelling experiments 
were performed. With this technique, deposition of the brown 
peroxidase-based stain with the first primary antibody blocks 
subsequent staining of those cells with the second primary 
antibody linked to alkaline phosphatase. This same phenomenon 
has been observed previously for staining of human mast cells 
(Irani et al. 1986, 1989}. In lung, Figure 16A shows 2 brown 
tryptase-positive cells. These cells remain brown while 2 
others stain blue with the anti-chymase antibody (Figure 16B} . 
By sequential staining, tryptase-positive cells in lung 
accounted for 84 ± 7% of the chymase I-positive cells (Table 
5). In skin, a section is shown that contains one tryptase-
positive cell (Figure 16C} and one chymase I-positive cell 
(Figure 16D} . Tryptase-positive cells in skin account for 7 
± 1% of the chymase I-positive cells (Table 5) . In peritoneal 
cells, Figure 16E shows 5 tryptase-positive cells; subsequent 
staining with anti-chymase I antibody reveals an additional 9 
chymase I-positive cells (Figure 16F} . About 13 ± 7% of the 
chymase I-positive cells in peritoneal lavage fluid are also 
tryptase-positive (Table 5). 
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Figure 16. Sequential Double Labeling With Anti-Tryptase And 
Anti-Chymase I Antibodies. Sections of lung (A, B) and skin 
(C, D), and a cytospin of peritoneal cells (E, F} were 
incubated first with goat IgG anti-tryptase and developed with 
peroxidase-conjugated swine anti-goat IgG (brown) (A, C, E). 
Sections and cytospin were then incubated with rabbit IgG 
anti-chymase I antibody and developed with alkaline 
phosphatase-conjugated goat anti-rabbit IgG (blue) (B, D, F). 
Cells with tryptase stained brown and remained brown; those 
with chymase I became blue only if tryptase was not present. 
Panel E was photographed under phase contrast. 
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Cell Source Cells* \Tcyptase+ 
(n) %-Chymase 1+ ** 
± SD 
-
Peribronchus 40-50 84/16 ± 7 
(4) 
Dermis 156-412 7/93 ± 9 
(4) 
Peritoneal 105-264 13/87 ± 7 
(12) 
Table 5. Sequential Labeling Of Tryptase And Chymase I. The results of sequential 
double labeling of mast cells· with anti-tryptase and anti-chymase I are sununarized in 
the table. SD, standard deviation; n, number of tissues used in the experiments; *, 
number of cells counted per section or slide; **, refers to ChymAse r+/Tryptase· mast 
cells. 
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CHAPTER X 
DISCUSSION 
Rat Mast Cell Heterogeneity. 
Although rat tryptase has been purified from skin 
(Braganza & Simmons 1991) and peritoneal cells (Kido et al. 
1985), its cellular localization has never been formally 
determined in this species. In the current study, a goat 
polyclonal IgG antibody prepared against purified rat skin 
tryptase was used to determine the distribution of tryptase in 
rat skin, lung, bowel mucosa and peritoneal cells. The 
antibody was produced in high titer, as determined by ELISA, 
and was specific, as determined by Western blotting with 
extracts from lung, skin and peritoneal cells. Although the 
level of endogenous tryptase (approximately 0.003% of total 
protein) was too low for detection by this technique, 
exogenously added tryptase, but no other proteins, were 
detected. By a variety of histochemical and 
immunohistochemical techniques, tryptase 
exclusively in mast cells, but only in a 
connective tissue type of mast cell. 
was localized 
subset of the 
Localization to mast cells was demonstrated by sequential 
staining with alcian blue and anti-tryptase antibody. Only 
the blue mast cells were stained by the antibody. However, 
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although about 50% of mast cells in lung contained tryptase, 
most in skin, bowel and peritoneal cells did not contain 
tryptase. Before examining the distribution of tryptase among 
mucosa! and connective tissue mast cells, the distributions of 
these two mast cell types were assessed histochemically, by 
sequential staining with alcian blue and safranin. Mucosa! 
mast cells stain blue; mature connective tissue mast cells 
stain red. This sequential staining technique showed that 
lung tissue contained similar numbers of both mast cell types. 
Skin and peritoneal mast cells were almost exclusively of the 
connective tissue type, while those in the bowel mucosa were 
almost exclusively of the mucosa! type. These distributions 
are similar to those previously reported (Enerback 1981, 
Gibson & Miller 1986, Huntley et al. 1990). Sequential 
staining with safranin and anti-tryptase antibody, in part, 
clarified the localization of tryptase. Safranin stains 
heparin-containing mast cells, and therefore is a marker of 
the mature connective tissue type of mast cell. Tryptase was 
present only in safranin-stained cells, but not in all 
connective tissue mast cells. This varied from tissue to 
tissue. The percentage of connective tissue mast cells 
staining for tryptase was 94% for lung, 20% for peritoneal 
cells, and 6% for skin. Thus, even though tryptase was 
purified from skin, the percentage of mast cells containing 
the enzyme in skin is markedly lower than in lung. The amount 
of tryptase in skin mast cells is also lower than that in lung 
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mast cells as indicated by weaker tryptase stain in the skin 
mast cells. 
To confirm localization of tryptase to the connective 
tissue type mast cells, double labeling experiments were 
performed with anti-tryptase and anti-chymase I antibodies. 
Mast cell-specific chymases have been chosen to be markers 
that distinguish mast cells from other cell types, and mast 
cell subsets from one another (Karger 1990). In the rat, 
chymase I (also called rat mast cell protease I) is found only 
in connective tissue mast cells while chymase II (also celled 
rat mast cell protease II) is found only in mucosal mast 
cells (Miller et al. 1990). Using the simultaneous double 
labelling technique, all tryptase-stained mast cells in skin 
and peritoneal lavage cells also stained for chymase I. Only 
in lung was there a suggestion that tryptase could reside in 
mast cells lacking chymase I. In this case 4% of tryptase-
stained mast cells did not develop detectable staining for 
chymase I by the simultaneous labeling technique. We view 
this as an upper limit, because variations in staining 
intensity from one cell to the next in tissue sections may 
lead to a more intense tryptase stain followed by a less 
intense stain for chymase I which, at the extreme, may not be 
detectable by this technique. Thus, the existence of a minor 
population of tryptase-positive, chymase I-negative cells in 
lung is questionable. 
To more easily determine the distribution of tryptase 
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among the connective tissue mast cells, sequential rather than 
simultaneous double labelling was used. Staining with anti-
tryptase antibodies was followed by staining with anti-chymase 
I antibodies such that tryptase-positive cells retained the 
stain for tryptase (even though they also contained chymase I} 
while those negative for tryptase stained for chymase I. The 
percentage of connective tissue mast cells that contained 
tryptase by this sequential chymase I technique compared with 
the simultaneous chymase I technique and the sequential 
safranin technique were similar: 84, 80 and 94 for lung; 7, 4 
and 6 for skin; and 13, 15 and 20 for peritoneal cells. Thus, 
rat tryptase is present in a subset of the connective tissue 
type of mast cell. 
Our results for tryptase in rat tissues more closely 
parallel previously made observations in mouse than in human. 
In human, all mast cells contain tryptase, whereas only a 
subset contain chymase (only one chymase in humans}, 
carboxypeptidase and a cathepsin G-like protease (Irani & 
Schwartz 1990}. In the mouse, cDNA molecules for at least 5 
chymases, 2 tryptases and 1 carboxypeptidase have been 
identified (Reynolds et al. 1990a, 1990b}. Northern blots 
with tissue extracts enriched for mucosa! and connective 
tissue mast cells suggest that mouse tryptase (MMCP-6}, like 
rat tryptase, is located in connective tissue mast cells, 
whereas chymases are distributed either in mucosa! or 
connective tissue mast cell types or both. 
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The finding that only a subpopulation of connective 
tissue mast cells contain tryptase in the rat indicates a 
greater degree of heterogeneity than anticipated. One 
possible explanation for this finding is that tryptase 
expression is pennissible only in connective tissue mast 
cells, but is regulated and inducible by environmental 
factors. An alternative explanation is that there are at 
least three distinct subsets of mast cells: tryptase-positive, 
chymase I-positive, chymase II-negative; tryptase-negative, 
chymase I-positive, chymase II-negative; and tryptase-
negative, chymase I-negative, chymase II-positive. Further 
studies will be needed to clarify that to what extent mast 
cell heterogeniety is due either to lineage or to environment. 
156 
SUMMARY 
Tryptase was purified from rat skin and found to be a 
glycoprotein with an apparent molecular weight of about 31, 000 
on SDS-PAGE gels. Incubation of the enzyme with N-glycanase 
converted the enzyme from a broad band to a sharp single band 
with a molecular weight of approximately 27,000. The amino 
acid sequences of the N-terminus, four tryptic peptides, and 
one lysylendopeptidase-C peptide were determined by the Edman 
procedure. These sequences accounted for 119 amino acids or 
about 45% of the total primary structure. The peptides have 
an overall 81-82% identity to human tryptases, 75% to dog 
tryptase, 77% to mouse tryptase-1, 93% to mouse tryptase-2, 
and 43% to bovine trypsin. Among the peptides sequenced are 
the active site region containing the catalytic serine residue 
and the substrate-binding aspartate. Two putative 
glycosylation sites have been identified. One of them is 
highly conserved among tryptases. The other only appears in 
mouse tryptase-2 but not the other tryptases. Four of the 
five tryptophan residues unique to tryptases but not to 
trypsin were found in the peptide sequences. The results 
revealed considerable structural differences between tryptase 
and trypsin as well as some significant structural variations 
among tryptases. This work has provided a solid support for 
future studies on the correlation of the functional 
characteristics of tryptases to their structural properties. 
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The cellular distribution of rat tryptase was examined in 
rat skin, lung, small intestine and peritoneal lavage cells by 
immunohistochemical techniques. Tryptase purified to apparent 
homogeneity from rat skin was used to generate goat polyclonal 
anti-rat tryptase antibody. Western blotting of extracts of 
skin, lung and peritoneal cells showed that the antibody was 
specific for rat tryptase. Tryptase containing cells were 
detected in lung, skin, and peritoneal lavage cells. Small 
intestinal mucosa, on the other hand, was found to have few, 
if any, tryptase-positive cells. Sequential staining with 
alcian blue and anti-tryptase antibody showed that tryptase 
was located only in mast cells. Sequential staining with 
safranin to identify the connective tissue type of mast cell, 
and anti-tryptase antibody showed that tryptase resides only 
in this mast cell type. However, only a subpopulation of the 
safranin-positive mast cells contained tryptase. In lung, 53% 
of the mast cells stained with safranin, and 94% of these were 
tryptase-positive. In skin, 80% of the mast cells stained 
with safranin, but only 6% of these were tryptase-positive. 
In peritoneal cells, more than 95% of the mast cells were 
safranin-positive, but onle 20% of these were tryptase-
positive. In the bowel mucosa, where few safranin-positive 
cells exist, no tryptase-positive cells were detected. The 
simultaneous and sequential double-labeling with anti-tryptase 
and anti-chymase I antibodies were performed to confirm and 
extend the histochemical findings. The percentages of chymase 
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I-positive cells that were tryptase-positive by the 
simultaneous and sequential techniques, respectively, were 80 
and 84 for lung, 4 and 7 for skin, and 15 and 13 for 
peritoneal cells. The data from our study suggest that the 
rat connective tissue type of mast cell is subdivided into two 
forms based on the presence or absence of tryptase. Rat 
mucosa! mast cells are devoid of skin-derived tryptase, 
although it is possible that a tryptase could reside in 
mucosal mast cells that lacks immunological crossreactivity. 
These results contrast with those in humans, where tryptase is 
present in all mast cells. However, the results are similar 
to those in the mouse, where tryptase mRNA has been detected 
only in the connective tissue type. 
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APPENDIX A: ENZYME PURIFICATION SOLUTIONS 
Homogenization Buffer: 
Dissolve 9.29 g of sodium phosphate monobasic, 43.9 g of 
sodium phosphate dibasic, 6.27 g of EDTA, and 438 g of 
NaCl in 15 1 of Milli Q {MQ) water. The solution 
contains 25 mM of sodium phosphate, 1 mM EDTA, and 0.5 M 
of NaCl, pH 7. 
Dialysis Buffer: 
Dissolve 69 g of sodium phosphate monobasic, 8.3 g of 
EDTA, and 584.4 g of NaCl in MQ water; adjust to pH 6, 
and bring the volume to 20 1 with MQ water. The solution 
contains 25 mM of sodium phosphate, 1 mM of EDTA, and 0. 5 
M of NaCl. 
PAB Wash Buffer: 
in Dissolve 14.6 g of NaCl, and 240.4 g of urea 
homogenization buffer to a final volume of 500 ml. The 
1 mM final solution contains 25 mM sodium phosphate, 
EDTA, 1 M NaCl, and 8 M urea, pH 7. 
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PAB Equilibration Buffer: 
Dissolve 3.45 g of sodium phosphate monobasic, 0.2 g of 
NaN3 , and 29.2 g of NaCl, adjust to pH 6, and bring the 
volume to 1 1 in MQ water. The final solution contains 
25 rnM of sodium phosphate, O. 5 M of NaCl, and o. 02%' 
(w/v) of NaN3 • 
PAB Elution Buffer: 
Dissolve 1566 mg of benzarnidine in 100 ml of the PAB 
equilibration buffer. The final solution contains 25 rnM 
sodium phosphate, 0.5 M NaCl, 0.02%' NaN3 , and 0.1 M 
benzarnidine, pH 6. 
Con-A Activation Buffer: 
Dissolve 6.8 g of sodium acetate, 10.2 g MgC12 , 29.2 g of 
NaCl, 555 mg of CaC12 , and 100 mg of NaN3 ; adjust to pH 6, 
and bring to 500 ml in MQ water. The final solution 
contains 100 mM of sodium acetate, 100 rnM of MgC12 , 1 M 
of NaCl, 10 mM of CaC12 , and 0.02%' of NaN3 • 
Con-A Elution Buffer: 
Dissolve 10 g of ~-methyl-D-rnannoside in 100 ml of the 
PAB equilibration buffer. The final solution contains 25 
rnM of sodium phosphate, 0.5 M of NaCl, 0.02%' of NaN3 , and 
100 mg/ml of the rnannoside, pH 6. 
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Con-A Wash Buffer: 
Dissolve 987.5 mg of Tris-HCl, and 168 mg of EDTA in MQ 
water; adjust to pH 6, and bring the volume to 250 ml. 
The final solution contains 25 mM Tris-HCl, and 2 mM 
EDTA. 
Enzyme Assay Buffer: 
Dissolve 709.8 mg of sodium phosphate dibasic and 67.2 mg 
of EDTA in MQ water; adjust to pH 7.5, and bring the 
volume to 200 ml. The solution contains 25 mM sodium 
phosphate and 1 mM of EDTA. 
10 mM BAEE Solution: 
Dissolve 17.14 mg of BAEE in 5 ml of MQ water; stored at 
4 °C. 
APPENDIX B. SDS-PAGE SOLUTIONS 
Sample Buffer: 
The solution contains 2. St of SDS (2S µl of 2ot SDS 
stock), 10 mM of Tris and 1 mM EDTA (0.1 ml of 20 mM 
Tris, 2 mM EDTA), o.s mM DTT (lS µl of 10 mM/ml DTT), and 
O.Olt of Bromophenol Blue (2 µl of lt Bromophenol Blue). 
sot Ethanol, lOt Acetic Acid: 
Mix SO ml of lOOt ethanol with 40 ml MQ water, then add 
10 ml of acetic acid. 
lOt Ethanol, St Acetic Acid: 
Mix SO ml of lOOt ethanol with 42S ml water, then add 2S 
ml acetic acid. 
8.3t Glutaraldehyde: 
Mix 40 ml of the 2St commercial glutaraldehyde with 80 ml 
of MQ water. 
0.2S% Silver Nitrate: 
Desolve 2SO mg of silver nitrate in 100 ml MQ water. Make 
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this solution fresh. 
Developer: 
12. 5% Na2C03 stock: Disolve 25 g of Na2C03 in 200 ml of MQ 
water. Prior to the experiment, mix so ml of the 12.5% 
Na2C03 stock with 200 ml of MQ water. 
5% Acetic Acid (v/v) : 
Add 5 ml of acetic acid to 95 ml of MQ water. 
10% Acetic Acid, 6% Glycerol (v/v) : 
Desolve 6 ml of glycerol in 84 ml of MQ water; add 10 ml 
of acetic acid. 
APPENDIX C: ALKYLATION SOLUTIONS 
Tris-HCl Buffer: 
Dissolve 18.17 g of Tris-Base and 500 mg of EDTA in MQ 
water; adjust to pH 8. 6 and bring to 100 ml. The 
solution contains 1.5 M Tris and 5 mg/ml EDTA. 
Iodo- [3H] Acetic Acid Solution: 
Dissolve 1 mCi of the iodo[2- 3H]acetic acid in 0.1 ml of 
MQ water to give a 0.1 mCi/ml solution. The specific 
activity was 175 mCi/mmol. 
Cold Iodoacetic Acid Solution: 
Dissolve 14.5 mg of iodoacetic acid in 108 µl of 0.5 N 
NaOH to 134 mg/ml. 
6 N HCl Solution: 
Add 500 µl of the concentrated HCl slowly to 500 µl of MQ 
water under the hood. 
100 mM Ammonium Bicarbonate Buffer: 
Dissolve 3.95 g of NH4HC03 in 500 ml MQ water and adjust 
to pH 8. 
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9% Formic Acid: 
Mix 51 ml of the 88% formic acid stock with 449 ml of MQ 
water. 
APPENDIX D: WESTERN BLOT SOLUTIONS 
Homogenization Buffer: 
Dissolve 976 mg of MES and 14.5 g of NaCl in MQ water; 
adjust to pH 6 and bring to a final volume of 500 ml with 
water. The solution contains 10 mM MES and 0.5 M NaCl. 
Chymase Assay Buffer: 
Dissolve 960 mg of Tris-Base and 1.47 g of CaC12, adjust 
to pH 7. 8 and bring to 500 ml with MQ water. The 
solution contains 80 mM Tris and 100 mM CaC12 • 
1 mM BTEE {N-Benzoyl-L-Tyrosine Ethyl Ester) : 
Dissolve 16.8 mg of BTEE in 25 ml of methanol and bring 
the volume to 50 ml with MQ water. 
20% TCA: 
Mix 0. 8 ml of trichloroacetic acid with 3. 2 ml of MQ 
water. 
Staining Solution: 
Dissolve 1 PhastGel Blue R tablet in 80 ml of MQ water; 
stir for 10-15 minutes; add 120 ml of methanol; stir 
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again for 2 minutes, and then filter the solution which 
contains 0.2% PhastGel Blue R. 
Mix 10 ml of the 0.2% PhastGel Blue R with 90 ml of 20% 
acetic acid. 
Destaining Solution (30% Methanol and 10% Acetic Acid): 
Add 90 ml of methanol to 180 ml of MQ water; add 30 ml of 
acetic acid to the above. 
Preservative Solution (5% Glycerol and 10% Acetic Acid) : 
Mix 5 ml of glycerol with 85 ml of MQ water; add 10 ml of 
acetic acid. 
PhastTransfer Buffer: 
Dissolve 1.5 g Tris-Base and 7.2 g glycine in 400 ml of 
MQ water; add 100 ml of methanol. The solution contains 
25 mM Tris, 192 mM of glycine, and 20% methanol, pH 8.3. 
10 X TBS: 
Dissolve 6 g of Tris-Base and 43.5 g of NaCl; adjust to 
pH 7.5 and bring the volume to 500 ml with MQ water. 
1 X TBS: 
Make a 1:10 dilution from the 10 X TBS solution with MQ 
water. The final solution contains 10 mM of Tris and SO 
mM NaCl, pH 7.5. 
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Blocking Buffer (3% BSA/TBS) : 
Dissolve 3 g of bovine serum albumin, fraction V in 100 
ml of the 1 X TBS. 
0.5% BSA/TBS: 
Dissolve 0.5 g of BSA in 100 ml of the 1 X TBS. 
Second Antibody Solution: 
Dilute 15 µl of the peroxidase or alkaline phosphatase 
conjugated secondary antibody in 15 ml of the o. 5% 
BSA/TBS. 
AEC/~02 Solution: 
See appendix F. 
APPENDIX E: TISSUE SECTION PREPARATION 
Carney's Solution: 
In a bottle, mix 60 ml of 100% ethanol, 30 ml chloroform, 
and 10 ml glacial acetic acid. Store the solution at 4 
°C. The final solution contain s 60% ethanol, 30% 
chloroform, and 10% acetic acid. 
PBS (Phosphate Balanced Saline) : 
Dissolve 8 g of NaCl, O. 2 g of KCl, 1. 44 g of Na2HP04 and 
0.24 g K~P04 in 800 ml of MQ water; adjust to pH 7.4 with 
HCl and add water to 1 liter. 
PBS/Heparin Buffer: 
Dissolve 80 mg of gelatin in 80 ml of PBS by stirring on 
a hot plate; cool the solution to room temperature; add 
0.8 ml of 1000 U/ml of heparin. 
PBS/DNase Buffer: 
Dissolve 10 mg of gelatin in 10 ml of PBS by stirring on 
a hot plate; cool the solution to room temperature; add 
10 µl of DNase at 10 mg/ml. 
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~02/Methanol Solution: 
Add O. 8 ml of 30% ~02 to 40 ml of methanol. The solution 
which contains 0.6% of ~02 in methanol was made prior to 
the reaction. 
APPENDIX F: IMMUNOHISTOCHEMICAL STAINING 
0.5% Alcian Blue Solution: 
Dissolve 0.5 g of alcian blue 8 GX in 100 ml of MQ water 
by stirring; adjust to pH 1 with concentrated HCl; filter 
through a No. 4 filter from Millopore. The solution is 
stable for a few months at room temperature. 
0.1% Safranin O Solution: 
Add 1 ml of glacial acetic acid to 99 ml of MQ water; 
dissolve 0.1 g of safranin O in 100 ml of the 1% acetic 
acid solution. The solution is stable for a few months 
at room telnperature. 
PBS/BSA Solution: 
Dissolve 1 g of bovine serum albumin fraction V and 10 mg 
of thimersol in 100 ml of BSA {appendix E); store the 
solution at 4 °C. 
TTBS: 
Dissolve 24 g of Tris-Base, 36 g of NaCl, 0.4 g 
thimersol, and 2 ml of Tween-20; adjust to pH 7.4; bring 
to 4 1 with MQ water; store in 500 ml aliquot at 4 °C. 
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AEC/~02 Solution: 
O .1 M acetic acid solution: Add 1.16 ml of glacial 
acetic acid in 100 ml of MQ water for solution A; 
dissolve 2.72 g of sodium acetate.3~0 in 100 ml of MQ 
water for solution B. Mix 14.8 ml of solution A with 3S.2 
ml of solution Band SO ml of MQ water; adjust to pH S.2 
to render a 0.1 M acetic acid solution. 
AEC solution: Dissolve 20 mg of 3-amino-9-
ethylcarbazole in S ml of N-N-dimethylformimide; add 100 
ml of the O .1 M acetic acid solution; stir at room 
temperature for S minutes; filter the solution through a 
0.45 µm membrane; store the AEC in 1 ml aliquot at -20 
oc. 
Mix 29 ml MQ water with 1 ml of the 30% 
commercial ~02 stock. 
The AEC/H202 solution is prepared prior to the reaction by 
adding 10 µl of the 1% ~02 to the 1 ml AEC. 
DAB/H202 Solution: 
DAB solution: Dissolve 3 g of Tris-Base in SOO ml MQ 
water; adjust to pH 7.6 with HCl to form a O.OS M Tris 
buffer; dissolve 5 mg of diaminobenzidine in 10 ml of the 
O. OS M Tris buffer; stir at room temperature for S 
minutes; filter through a 0.4S µm membrane. 
1% ~02 : Mix 29 ml MQ water with 1 ml of the 30% 
commercial ~02 stick. 
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Add 10 µl of the 1% ~02 to 1 ml of the DAB solution. The 
DAB/~02 solution must be prepared fresh every time prior 
to the reaction. 
Naphthol/Fast Blue Solution: 
0.1 M Tris buffer: Dissolve 6.05 g of Tris-Base in 500 
ml of MQ water; adjust to pH 8.2; store at 4 °C. 
Prior to the reaction, dissolve 5 mg of naphthol AS-MX in 
0.5 ml of N,N-dimethylformimide; add 24.5 ml of the 0.1 
M Tris buffer warmed to 37 °C; add 6 mg of levarnisole; 
dissolve 5-10 mg of Fast Blue RR in the above solution to 
1 mg/ml; filter and use the solution within 20-30 
minutes. 
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